

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS	3	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/CAPLUS.
NEWS	4	OCT 21	CA/CAPLUS kind code changes for Chinese patents increase consistency, save time
NEWS	5	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
NEWS	6	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
NEWS	7	NOV 03	New format for Korean patent application numbers in CA/CAPLUS increases consistency, saves time.
NEWS	8	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
NEWS	9	NOV 18	PROUSDDR and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prous Science
NEWS	10	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching
NEWS	11	NOV 24	Search an additional 46,850 records with MEDLINE backfile extension to 1946
NEWS	12	DEC 14	New PNK Field Allows More Precise Crossover among STN Patent Databases
NEWS	13	DEC 18	ReaxysFile available on STN
NEWS	14	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS	15	DEC 22	Value-Added Indexing Improves Access to World Traditional Medicine Patents in CAPLUS
NEWS	16	JAN 24	The new and enhanced DPCI file on STN has been released
NEWS	17	JAN 26	Improved Timeliness of CAS Indexing Adds Value to USPATFULL and USPAT2 Chemistry Patents
NEWS	18	JAN 26	Updated MeSH vocabulary, new structured abstracts, and other enhancements improve searching in STN reload of MEDLINE
NEWS	19	JAN 28	CABA will be updated weekly

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer

agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:56:40 ON 11 FEB 2011

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.23

0.23

FILE 'REGISTRY' ENTERED AT 09:57:22 ON 11 FEB 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 FEB 2011 HIGHEST RN 1262583-27-6

DICTIONARY FILE UPDATES: 10 FEB 2011 HIGHEST RN 1262583-27-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10590845.str



chain nodes :

10 17

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16

chain bonds :

```

9-10 10-11
ring bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16
exact/norm bonds :
1-7 2-9 7-8 8-9 9-10
exact bonds :
10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS


```

L1 STRUCTURE UPLOADED

```

=> d
L1 HAS NO ANSWERS
L1 STR

```



Structure attributes must be viewed using STN Express query preparation.

```

=> s l1
SAMPLE SEARCH INITIATED 09:57:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1026 TO ITERATE

100.0% PROCESSED 1026 ITERATIONS 23 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS: 18599 TO 22441
PROJECTED ANSWERS: 173 TO 747

```

L2 23 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 09:58:08 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 20169 TO ITERATE

100.0% PROCESSED 20169 ITERATIONS

524 ANSWERS

SEARCH TIME: 00.00.01

L3 524 SEA SSS FUL L1

=> s l3 and caplus/lc

73628895 CAPLUS/LC


L4 446 L3 AND CAPLUS/LC

=> s l3 not l4

L5 78 L3 NOT L4

=> d l5 78


L5 ANSWER 78 OF 78 REGISTRY COPYRIGHT 2011 ACS on STN
RN 581092-10-6 REGISTRY
ED Entered STN: 08 Sep 2003
CN Propanamide,
N-[2-butyl-7-methyl-3-[(4-nitrophenyl)methyl]-3H-imidazo[4,5-
b]pyridin-6-yl]-2,2-dimethyl- (CA INDEX NAME)
MF C23 H29 N5 O3
SR Chemical Library
Supplier: AsInEx
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> d 13 70

L3 ANSWER 70 OF 524 REGISTRY COPYRIGHT 2011 ACS on STN
RN 864172-18-9 REGISTRY
ED Entered STN: 29 Sep 2005
CN 4-Piperidinemethanamine, 1-methyl-N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)
MF C23 H31 N5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d 13 71-77

L3 ANSWER 71 OF 524 REGISTRY COPYRIGHT 2011 ACS on STN
 RN 864172-17-8 REGISTRY
 ED Entered STN: 29 Sep 2005
 CN 4-Piperidinemethanamine, 1-(tetrahydro-2H-pyran-4-yl)-N-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)- (CA INDEX NAME)
 MF C27 H37 N5 O
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 72 OF 524 REGISTRY COPYRIGHT 2011 ACS on STN
 RN 864172-16-7 REGISTRY
 ED Entered STN: 29 Sep 2005
 CN 4-Piperidinemethanamine, N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)
 MF C22 H29 N5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 73 OF 524 REGISTRY COPYRIGHT 2011 ACS on STN
 RN 864172-15-6 REGISTRY
 ED Entered STN: 29 Sep 2005
 CN 4-Piperidinemethanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1-(1-methylethyl)- (CA INDEX NAME)
 MF C26 H37 N5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 74 OF 524 REGISTRY COPYRIGHT 2011 ACS on STN
 RN 864172-14-5 REGISTRY
 ED Entered STN: 29 Sep 2005
 CN 2H-Pyran-4-amine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]tetrahydro- (CA INDEX NAME)
 MF C22 H28 N4 O
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 75 OF 524 REGISTRY COPYRIGHT 2011 ACS on STN
 RN 864172-13-4 REGISTRY
 ED Entered STN: 29 Sep 2005
 CN 4-Piperidinemethanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)
 MF C28 H39 N5 O
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L3 ANSWER 76 OF 524 REGISTRY COPYRIGHT 2011 ACS on STN
 RN 864172-12-3 REGISTRY
 ED Entered STN: 29 Sep 2005
 CN 2H-Pyran-4-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]tetrahydro- (CA INDEX NAME)
 MF C23 H30 N4 O
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 77 OF 524 REGISTRY COPYRIGHT 2011 ACS on STN
 RN 864172-11-2 REGISTRY
 ED Entered STN: 29 Sep 2005
 CN Cyclohexanol, 4-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]methyl]-, trans- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H32 N4 O
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	223.44	223.67


FILE 'CAPLUS' ENTERED AT 09:59:45 ON 11 FEB 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Feb 2011 VOL 154 ISS 8
FILE LAST UPDATED: 10 Feb 2011 (20110210/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

Caplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 200902019142	A1	20091126	US 2009-468706	20090519
AR 71884	A1	20100721	AR 2009-101846	20090522
WO 2009144201	A1	20091203	WO 2009-EP56311	20090525
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, AY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			EP 2008-156933	A 20080526
OTHER SOURCE(S):		MARPAT 152:12353		
GI				




AB The title compds. I [R1 = C,alkyl optionally substituted by halo; R2, R3 = H, alkyl; XY = C,tipbond=C, CH=CH, CH=CF, CH2CH2, NHCO, CONH; Z = CH2, (CH2)2, (CH2)4, CO, a bond; R4 = H, alkyl and R5 = alkyl substituted by heterocyclyl; or NR4R5 = heterocyclyl or heteroaryl], useful in the treatment of diseases and disorders which may e.g. involve angiogenesis and/or pain, including autoimmune and inflammatory diseases, were prepared.

prepared. For example, a multi-step synthesis of II, starting from 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine and 4-iodobenzyl bromide, was given. Exemplified compds. I were tested in cell-based assay for human GPR4 activity. For example, II showed IC50 of 189 nM. Pharmaceutical compns. comprising the compound I, alone or in combination with other therapeutic agent, were disclosed.


IT	With other therapeutic agent, were also tested.
IN	1978-86-9 1978-9-30 8-1P
RI:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
RD	Preparation of novel imidazopyridine derivs. as GPR4 receptor modulators
NR	for treating angiogenesis, pain, autoimmune and inflammatory diseases)
IN	1978-79-86-9 CAPLUS
CN	1,4-dimethyl-2,3,4,5-tetrahydro-6H-imidazo[4,5-b]pyridine-6-carboxamide, N-[4-((2-methyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-2-yl)methyl)phenyl]- (CA INDEX NAME)




L6 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
CN 1-Piperidinepentanamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



RN 1197879-88-1 CAPLUS
CN 1-Pyrrolidinepentanamide,
3-(dimethylamino)-N-[4-[(2-ethyl-5,7-dimethyl-3H-
imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




IT 1197880-45-7P
 RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT (Reactant or reagent)
 (preparation of novel imidazopyridine derivs. as GPR4 receptor
 modulators
 for treating angiogenesis, pain, autoimmune and inflammatory diseases)
 RN 1197880-45-7 CAPLUS
 CN Pentanamide,
 5-chloro-N-[4-[(1-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-
 3-yl)methyl]phenyl]- (CA INDEX NAME)




IT	137421-61-5P
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
	(preparation of novel imidazopyridine derivs. as GPR4 receptor modulators for treating angiogenesis, pain, autoimmune and inflammatory diseases)
RD	137421-61-5 CAPLUS
CN	Benzenamine, 4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl-, (CA INDEX NAME)

L6 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



L6 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2007:364454 CAPLUS
 DOCUMENT NUMBER: 147:38462
 TITLE: A novel method for assessing inhibition of ibuprofen chiral inversion and its application in drug discovery
 AUTHOR(S): Reddy, Anita; Hashim, Muhammed; Wang, Ziqiang; Penn, Lara; Stankovic, Charles J.; Burdette, Douglas; Surendran, Narayanan; Cai, Hongliang
 CORPORATE SOURCE: Preclinical Discovery-Development, Ann Arbor Laboratories, Pfizer Global Research and Development, Ann Arbor, MI, 48105, USA
 SOURCE: International Journal of Pharmaceutics (2007), 335(1-2), 63-69
 CODEN: IJPHDE; ISSN: 0378-5173
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB An inhibition assay to assess the potential for chiral inversion of compds. was developed using R(-)-ibuprofen as the probe substrate. Inhibition of the chiral inversion of R(-)-ibuprofen by structurally similar compds. in cryopreserved rat hepatocytes was studied using chiral HPLC and LC/MS methods for the chromatog. separation and detection of enantiomers. Concept validation of this assay was performed with three com. available compds. and four Pfizer compds. The results of these studies demonstrated that compds. that are structurally similar to ibuprofen inhibited the formation of S(+)-ibuprofen, suggesting that they may undergo similar enzymic chiral inversion pathways or compete for the same enzyme active sites. Addnl., an application of this assay in early drug discovery for a specific class of compds. was demonstrated. Thirty-three inhouse compds. were screened for their chiral inversion potential utilizing this assay to investigate the structure activity relationship for this class of compds.
 IT 148550-05-4
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (ibuprofen chiral inversion inhibition assay and its application in drug discovery)
 RN 148550-05-4 CAPLUS
 CN 1H-Pyrrole-1-acetic acid, 2-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- α -(phenylmethyl)-, (α S)- (CA INDEX NAME)
 Absolute stereochemistry.




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L6 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2007:281164 CAPLUS
 DOCUMENT NUMBER: 146:309333
 TITLE: Preventives and/or remedies for X-ray induced lung injury containing GPR4 signaling inhibitors
 INVENTOR(S): Hiura, Naoko; Mie, Genya; Oshima, Etsuo; Manabe, Haruhiko; Watanabe, Akihiko
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 43pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007063261	A	20070315	JP 2006-207645	20060731

 PRIORITY APPLN. INFO.: JP 2005-223037 A 20050801


OTHER SOURCE(S): MARPAT 146:309333
 AB The invention provides a preventive and/or remedy for X-ray induced lung injury characterized by containing a component which inhibits signal transduction of GPR4 (G protein-coupled receptor 4), including an antisense an oligonucleotide, antibody, and imidazopyridine derivative
 For example, a compound 2-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-ylmethyl)-8-(4-methylpiperazin-1-ylmethyl)-10,11-dihydro[b,f]azepine difumarate was prepared, and examined for its GPR4 antagonistic effect and
 TNF- α production inhibitory effect in vitro.
 IT 137421-60-4P 137421-61-5P 927822-00-2P
 927822-02-4P 927822-04-6P 927822-05-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of preventives and/or remedies for X-ray induced lung injury containing GPR4 signaling inhibitors)
 RN 137421-60-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)




RN 137421-61-5 CAPLUS
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

L6 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)


L6 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 927822-00-2 CAPLUS
 CN Methanone, [4-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 927822-02-4 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester (CA INDEX NAME)



RN 927822-04-6 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 927822-05-7 CAPLUS
 CN Methanone, [4-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl](4-methyl-1-piperazinyl)-, ethanedioate (1:7) (CA INDEX NAME)

L6 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)

CM 1

CRN 927822-00-2
CMF C29 H40 N6 O



CM 2

CRN 144-62-7
CMF C2 H2 O4




IT 864171-66-4P 864172-38-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preventives and/or remedies for X-ray induced lung injury containing

GPR4 signaling inhibitors)

RN 864171-66-4 CAPLUS

CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[trans-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-38-3 CAPLUS

CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[cis-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L6 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:227775 CAPLUS

DOCUMENT NUMBER: 146:266782

TITLE: Chemokine production inhibitor

INVENTOR(S): Saki, Mayumi; Miura, Kazumi; Sasaki, Katsutoshi

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 83pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007023880	A1	20070301	WO 2006-JP316560	20060824
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2005-242994 A 20050824

OTHER SOURCE(S): MARPAT 146:266782

GI




AB Disclosed are a chemokine production inhibitor comprising a substance capable of inhibiting the function involved in signal transduction of GPR4 as an active ingredient; a chemokine production inhibitor comprising a nitrogenated

tricyclic compound represented by the formula I (R1 represents a (un)substituted heterocyclic group, -NR5aR5b where R5a and R5b independently represent H, a (un)substituted lower alkyl group or the like; R2 represents a H or the like; R3 and R4 independently represent a

H or the like; n = 0 or 1; X represents -(CH2)2 or the like; and Y represents the formula II where Z represents CH or N; R8a and R8b independently represent H, a (un)substituted lower alkyl group or the like; and R9 represents H or the like, or a quaternary ammonium salt or pharmacol. acceptable salt thereof as an active ingredient; and others. The chemokine production inhibitor includes antisense oligonucleotide and

L6 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



L6 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)

antibody which binds specified proteins. For example, a compd. 2-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-ylmethyl)-8-(4-methylpiperazin-1-ylmethyl)-10,11-dihydro[b,f]azepine difumarate was prepd., and examd. for its GPR4 antagonistic effect and IL-8 prodn. inhibitory effect in vitro.


IT 864171-83-5P 864171-86-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(chemokine production inhibitor comprising substances capable of inhibiting GPR4 signal transduction)

RN 864171-83-5 CAPLUS


CN Methanone, (4-methyl-1-piperazinyl)[trans-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 864171-86-8 CAPLUS
CN Cyclohexanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




IT 864172-71-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(chemokine production inhibitor comprising substances capable of inhibiting


L6 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
GPR4 signal transduction)
RN 864172-71-4 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



IT 864172-28-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chemokine production inhibitor comprising substances capable of inhibiting GPR4 signal transduction)
RN 864172-28-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)


Relative stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:1224882 CAPLUS
DOCUMENT NUMBER: 146:178505
TITLE: Identification of Previously Unrecognized Antiestrogenic Chemicals Using a Novel Virtual Screening Approach
AUTHOR(S): Wang, Ching Y.; Ai, Ni; Arora, Sonia; Erenrich, Eric; Nagarajan, Karthigeyan; Zauhar, Randy; Young, Douglas;
CORPORATE SOURCE: Welsh, William J.
Department of Pharmacology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School (UMDNJ-RWJMS), Piscataway, NJ, 08854, USA
SOURCE: Chemical Research in Toxicology (2006), 19(12), 1595-1601
CODEN: CRTOEC; ISSN: 0893-228X
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The physiol. roles of estrogen in sexual differentiation and development, female and male reproductive processes, and bone health are complex and diverse. Numerous natural and synthetic chemical compds., commonly known as endocrine disrupting chems. (EDCs), have been shown to alter the physiol. effects of estrogen in humans and wildlife. As such, these EDCs may cause unanticipated and even undesirable effects. Large-scale in vitro and in vivo screening of chems. to assess their estrogenic activity would demand a prodigious investment of time, labor, and money and would require animal testing on an unprecedented scale. Approaches in silico are increasingly recognized as playing a vital role in screening and prioritizing chems. to extend limited resources available for exptl. testing. Here, we evaluated a multistep procedure that is suitable for in silico (virtual) screening of large chemical databases to identify compds. exhibiting estrogenic activity. This procedure incorporates Shape Signatures, a novel computational tool that rapidly compares mol.s. on the basis of similarity in shape, polarity, and other bio-relevant properties. Using 4-hydroxy tamoxifen (4-OH TAM) and diethylstilbestrol (DES) as input queries, we employed this scheme to search a sample database of .apprx.200 000 com. available organic chems. for matches (hits). Of the eight compds. identified computationally as potentially (anti)estrogenic, biol. evaluation confirmed two as heretofore unknown estrogen antagonists. Subsequent radioligand binding assays confirmed that two of these three compds. exhibit antiestrogenic activities comparable to 4-OH TAM. Mol. modeling studies of these ligands docked inside the binding pocket of estrogen receptor α (ER α) elucidated key ligand-receptor interactions that corroborate these exptl. findings. The present study demonstrates the utility of our computational scheme for this and related applications in drug discovery, predictive toxicol., and virtual screening.
IT 921198-76-7
RL: BSU (Biological study, unclassified); BIOL (Biological study) (identification of previously unrecognized antiestrogenic chems. using a novel virtual screening approach)
RN 921198-76-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-5-amine, 2-butyl-6-methyl-3-[(4-

L6 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
nitrophenyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2005:985324 CAPLUS
DOCUMENT NUMBER: 143:272565
TITLE: pharmaceutical combination comprising a sulfonamide
INVENTOR(S): Kayakiri, Hiroshi; Kato, Takeshi; Minoura, Hideaki; Hirosumi, Jiro
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co. Ltd., Japan
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050197376	A1	20050908	US 2005-68747	20050302
WO 2005082414	A2	20050909	WO 2005-JP4022	20050302
WO 2005082414	A3	20060629		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2004-57555 A 20040302

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:272565
AB This invention provides a pharmaceutical combination containing a sulfonamide or a salt and a pharmaceutical selected from the group consisting of an α -glucosidase inhibitor, an insulin secretagogue, a sulfonylurea and a biguanide. The blood glucose level of a patient showed greater decrease by the combined administration of the test compound and a biguanide.
IT 275381-12-9


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical combination comprising sulfonamide)
RN 275381-12-9 CAPLUS
CN Carbamic acid, [3-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L6 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2005:979654 CAPLUS
 DOCUMENT NUMBER: 143:266925
 TITLE: Preparation of imidazo[4,5-b]pyridine derivatives as GPR4 receptor antagonists
 INVENTOR(S): Iida, Kyoichiro; Otsubo, Nobumasa; Kuboyama, Takeshi; Arai, Hitoshi; Watanabe, Akihiko; Saki, Mayumi; Hiura,
 Naoko; Manabe, Haruhiko; Takada, Hidenori; Saito, Jun
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 215 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082905	A1	20050909	WO 2005-JP3687	20050225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 2004-50933	A 20040226
			JP 2004-307947	A 20041022
OTHER SOURCE(S):			MARPAT 143:266925	
GI				




AB The title compds. I [wherein R1 = H, halo, NH2, etc.; R2-R4 = independently H, halo, CN, etc.; Y = N or (un)substituted CH; X = (un)substituted NH; Z1-Z4 = independently N or (un)substituted CH; W = NO2, CHO, (un)substituted alkyl, etc.] or pharmaceutically acceptable salts thereof are prepared as G protein-coupled receptor (GPR4) antagonists for the treatment of neutrophil inflammation. For example, the compound II was prepared in a multi-step synthesis. II inhibited 98% of human GPR4 at the concentration of 1 μ M.
 IT 863877-47-8P 863877-48-9P 863877-49-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists)
 RN 863877-47-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-3-[(4-fluoro-3-nitrophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)



RN 863877-48-9 CAPLUS
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-nitro- (CA INDEX NAME)



RN 863877-49-0 CAPLUS
 CN 1,2-Benzenediamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:286426
GI


AB The title compds. I [wherein R1 = H, halo, CN, etc.; A1-A2-A3-A4 = (un)substituted CH=CH-CH=CH2, N=CH-CH=CH, CH=N-CH=CH, CH=CH-N=CH, CH=CH-CH=N, N=CH-N=CH, CH=N-CH=N, or N=CH-CH=N; T = CHO = (un)substituted phenylene, naphthylene, heteroarylene, etc.; T = CHO = (un)substituted alkyl, cycloalkyl, etc.] or pharmaceutically acceptable salts thereof are prepared as G protein-coupled receptor (GPR4) antagonists for the treatment of neutrophilic inflammation. For example, the compound II was prepared in a multi-step synthesis. II inhibited 97% of human GPR4 at the concentration of 1 μ M.

IT	137421-62-6P	864171-56-2P	864171-57-3P
	864171-63-1P	864171-64-2P	864171-65-3P
	864171-67-5P	864171-68-6P	864171-71-1P
	864171-72-2P	864171-74-4P	864171-76-6P
	864171-79-9P	864171-81-3P	864171-83-5P
	864171-90-4P	864171-94-8P	864171-98-2P
	864172-00-9P	864172-01-0P	864172-02-1P
	864172-06-5P	864172-07-6P	864172-16-7P
	864172-23-6P	864172-24-7P	864172-27-0P
	864172-28-1P	864172-29-2P	864172-30-5P
	864172-31-6P	864172-35-0P	864172-37-2P
	864172-39-4P	864172-40-7P	864172-44-1P
	864172-51-0P	864172-53-2P	



RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists for treatment of neutrophilic inflammation)

RN	137421-62-6 CAPLUS
CN	Carbamic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl-, 1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)



RN 864171-57-3 CAPLUS
CN Methanone, [4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]phenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




Relative stereochemistry.

```


RN      864171-65-3  CAPLUS
CN      Methanone,
[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-
yl)methyl]phenyl]amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX
NAME)

```


Relative stereochemistry.



Relative stereochemistry.




Relative stereochemistry.




RN 864171-71-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 864171-72-2 CAPLUS
CN Methanone,
[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-1-piperazinyl- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-74-4 CAPLUS
CN Methanone,
[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl][4-(hydroxymethyl)-1-piperidinyl]- (CA INDEX NAME)

Relative stereochemistry.


RN 864171-81-3 CAPLUS
CN Methanone,
[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl][4-(4-morpholinyl)-1-piperidinyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-83-5 CAPLUS
CN Methanone, (4-methyl-1-piperazinyl)[trans-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-90-4 CAPLUS
CN Cyclohexanecarboxamide,
4-[[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.





RN 864171-76-6 CAPLUS
CN Cyclohexanecarboxamide, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-79-9 CAPLUS
CN Cyclohexanecarboxamide, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-94-8 CAPLUS
CN Cyclohexanecarboxamide, 4-[[4-[(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-98-2 CAPLUS
CN 4-Piperidinamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864172-00-9 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)


L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
b]pyridin-3-yl)methyl]phenyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864172-01-0 CAPLUS
CN 4-Piperidinemethanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



RN 864172-02-1 CAPLUS
CN 1,4-Dioxaspiro[4.5]decane-8-methanamine,
N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864172-06-5 CAPLUS
CN Cyclohexanone, 4-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]methyl]- (CA INDEX NAME)



RN 864172-07-6 CAPLUS
CN 1,4-Dioxaspiro[4.5]decan-8-amine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 864172-28-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-29-2 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)


Relative stereochemistry.




RN 864172-30-5 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[4-[(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.


L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 864172-16-7 CAPLUS
CN 4-Piperidinemethanamine,
N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



RN 864172-23-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864172-24-7 CAPLUS
CN 4-Piperidinemethanamine,
N-[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



RN 864172-27-0 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, cis- (CA INDEX NAME)


Relative stereochemistry.

L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 864172-31-6 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[4-[[2-(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-35-0 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-37-2 CAPLUS
CN Methanone, [cis-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-4-methyl-1-piperazinyl- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-39-4 CAPLUS
CN Methanone, [cis-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-4-morpholinyl- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-40-7 CAPLUS
CN Methanone, [cis-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-1-pyrrolidinyl- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-44-1 CAPLUS
CN Methanone, (4-methyl-1-piperazinyl)[cis-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-51-0 CAPLUS
CN Methanone, 4-morpholinyl[cis-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-53-2 CAPLUS
CN Methanone, 4-(hydroxymethyl)-1-piperidinyl[cis-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




IT 864170-95-6P 864170-96-7P 864170-97-8P
864170-98-9P 864170-99-0P 864171-00-6P
864171-01-7P 864171-02-8P 864171-03-9P
864171-04-0P 864171-05-1P 864171-06-2P
864171-07-3P 864171-08-4P 864171-09-5P
864171-10-8P 864171-11-9P 864171-12-0P
864171-13-1P 864171-14-2P 864171-15-3P
864171-16-4P 864171-17-5P 864171-18-6P
864171-19-7P 864171-20-0P 864171-21-1P
864171-22-2P 864171-23-3P 864171-24-4P
864171-25-5P 864171-26-6P 864171-27-7P
864171-28-8P 864171-29-9P 864171-30-2P
864171-31-3P 864171-32-4P 864171-33-5P
864171-34-6P 864171-35-7P 864171-36-8P
864171-37-9P 864171-38-0P 864171-39-1P
864171-40-4P 864171-41-5P 864171-42-6P
864171-43-7P 864171-44-8P 864171-45-9P
864171-46-0P 864171-47-1P 864171-48-2P
864171-49-3P 864171-50-6P 864171-51-7P
864171-52-8P 864171-53-9P 864171-54-0P
864171-55-1P 864171-58-4P 864171-60-8P
864171-61-9P 864171-62-0P 864171-66-4P
864171-69-7P 864171-70-0P 864171-73-3P
864171-75-5P 864171-78-8P 864171-80-2P
864171-82-4P 864171-84-6P 864171-85-7P
864171-86-8P 864171-87-9P 864171-88-0P
864171-89-1P 864171-91-5P 864171-92-6P
864171-93-7P 864171-95-9P 864171-96-0P
864171-97-1P 864171-99-3P 864172-03-2P
864172-04-3P 864172-05-4P 864172-09-8P
864172-10-1P 864172-11-2P 864172-12-3P
864172-13-4P 864172-14-5P 864172-15-6P
864172-17-8P 864172-18-9P 864172-19-0P
864172-20-3P 864172-21-4P 864172-22-5P
864172-25-8P 864172-32-7P 864172-33-8P
864172-34-9P 864172-36-1P 864172-38-3P
864172-42-9P 864172-43-0P 864172-45-2P
864172-46-3P 864172-48-5P 864172-49-6P
864172-50-9P 864172-52-1P 864172-54-3P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists for treatment of neutrophilic inflammation)


RN 864170-95-6 CAPLUS
CN Benzamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-fluoro- (CA INDEX NAME)




RN 864170-96-7 CAPLUS
CN Benzamide, 2-chloro-N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864170-97-8 CAPLUS
CN Benzamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864170-98-9 CAPLUS
CN Benzamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-methoxy- (CA INDEX NAME)




RN 864170-99-0 CAPLUS
CN Benzamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-methyl- (CA INDEX NAME)




RN 864171-00-6 CAPLUS
CN Acetamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-phenoxy- (CA INDEX NAME)




RN 864171-01-7 CAPLUS
CN Benzamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 864171-02-8 CAPLUS
CN Benzamide, 4-butoxy-N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-03-9 CAPLUS
CN Benzeneacetamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-methoxy- (CA INDEX NAME)




RN 864171-04-0 CAPLUS
CN Acetamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-methoxy- (CA INDEX NAME)



RN 864171-05-1 CAPLUS
CN Acetamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 864171-06-2 CAPLUS
CN Propanamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 864171-07-3 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-phenyl-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.




RN 864171-08-4 CAPLUS
CN Cyclopentanecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-09-5 CAPLUS
CN Cyclopentanepropanamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-10-8 CAPLUS
CN 2-Furancarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-11-9 CAPLUS
CN 1-Naphthalenecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-12-0 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-13-1 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-14-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-15-3 CAPLUS
CN 1,3-Benzodioxole-5-carboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-16-4 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-17-5 CAPLUS
CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide,
N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-18-6 CAPLUS
CN Benzanide,
3-cyano-N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-19-7 CAPLUS
CN Urea, N-(2-chlorophenyl)-N'-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-24-4 CAPLUS
CN Urea, N-(3-cyanophenyl)-N'-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-25-5 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-(1-naphthalenyl)- (CA INDEX NAME)




RN 864171-26-6 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-(3-nitrophenyl)- (CA INDEX NAME)




RN 864171-27-7 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-(phenylmethyl)- (CA INDEX NAME)




RN 864171-20-0 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 864171-21-1 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)




RN 864171-22-2 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-(4-methylphenyl)- (CA INDEX NAME)



RN 864171-23-3 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864171-28-8 CAPLUS
CN Urea, N-ethyl-N'-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-29-9 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.




RN 864171-30-2 CAPLUS
CN Urea,
N-cyclohexyl-N'-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-31-3 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-(1-methylethyl)- (CA INDEX NAME)




RN 864171-32-4 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-hexyl- (CA INDEX NAME)




RN 864171-33-5 CAPLUS
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)




RN 864171-34-6 CAPLUS
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 864171-35-7 CAPLUS
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 864171-40-4 CAPLUS
CN 2-Propanesulfonamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-41-5 CAPLUS
CN Benzenesulfonamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-42-6 CAPLUS
CN Benzenesulfonamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-methoxy- (CA INDEX NAME)




RN 864171-43-7 CAPLUS
CN Benzenesulfonamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-fluoro- (CA INDEX NAME)




RN 864171-36-8 CAPLUS
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 864171-37-9 CAPLUS
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, hexyl ester (9CI) (CA INDEX NAME)




RN 864171-38-0 CAPLUS
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)




RN 864171-39-1 CAPLUS
CN 1-Butanesulfonamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-44-8 CAPLUS
CN Benzenesulfonamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 864171-45-9 CAPLUS
CN 1-Naphthalenesulfonamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-46-0 CAPLUS
CN Benzenesulfonamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-3-nitro- (CA INDEX NAME)




RN 864171-47-1 CAPLUS
CN Benzenesulfonamide, 2,5-dichloro-N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-48-2 CAPLUS
CN Benzenesulfonamide,
N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-(trifluoromethoxy)- (CA INDEX NAME)




RN 864171-49-3 CAPLUS
CN 1-Naphthalenesulfonamide,
5-(dimethylamino)-N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-50-6 CAPLUS
CN 2-Naphthalenesulfonamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



RN 864171-51-7 CAPLUS
CN Benzenesulfonamide,
N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-



RN 864171-58-4 CAPLUS
CN Benzenemethanol, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 864171-60-8 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-, (2E)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 864171-59-5

CMF C29 H36 N6




CM 2


CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.




RN 864171-61-9 CAPLUS
CN 4-Piperidinamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1-methyl- (CA INDEX NAME)




RN 864171-52-8 CAPLUS
CN Ethanesulfonamide,
N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864171-53-9 CAPLUS
CN Benzenesulfonamide,
N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-methyl- (CA INDEX NAME)




RN 864171-54-0 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-phenyl- (CA INDEX NAME)



RN 864171-55-1 CAPLUS
CN Benzenamine, 3-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-phenyl- (CA INDEX NAME)




RN 864171-62-0 CAPLUS
CN Benzenamine, N-cyclohexyl-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 864171-66-4 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[trans-4-(4-methyl-1-piperazinyl)methyl]cyclohexyl- (CA INDEX NAME)

Relative stereochemistry.



RN 864171-69-7 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[trans-4-(4-morpholinylmethyl)cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 864171-70-0 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[trans-4-(1-pyrrolidinylmethyl)cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.

L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)




RN 864171-73-3 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(trans-4-(1-piperazinylmethyl)cyclohexyl)- (CA INDEX NAME)]

Relative stereochemistry.



RN 864171-75-5 CAPLUS
CN 4-Piperidinemethanol, 1-[[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl)methyl]- (CA INDEX NAME)]

Relative stereochemistry.




RN 864171-78-8 CAPLUS
CN 1-Pyrrolidineethanamine, N-[[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl)methyl]-, ethanedioate (1:?) (CA INDEX NAME)]

CM 1

CRN 864171-77-7
CMF C30 H44 N6

Relative stereochemistry.

L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 864171-80-2 CAPLUS
CN 4-Morpholineethanamine, N-[[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl)methyl]- (CA INDEX NAME)]

Relative stereochemistry.



RN 864171-82-4 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[trans-4-[[4-(4-morpholinyl)-1-piperidinyl)methyl]cyclohexyl]- (CA INDEX NAME)]


Relative stereochemistry.



L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)


RN 864171-84-6 CAPLUS
CN Benzenamine, N-[[trans-4-[[4-methyl-1-piperazinyl)methyl]cyclohexyl]-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)]

Relative stereochemistry.



RN 864171-85-7 CAPLUS
CN Cyclohexanecarboxamide, N-[2-(4-morpholinyl)ethyl]-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)]


Relative stereochemistry.



RN 864171-86-8 CAPLUS
CN Cyclohexanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)]


Relative stereochemistry.

L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)




RN 864171-87-9 CAPLUS
CN 4-Morpholineethanamine, N-[[trans-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl)methyl]- (CA INDEX NAME)]

Relative stereochemistry.




RN 864171-88-0 CAPLUS
CN Methanone, [4-(4-morpholinyl)-1-piperidinyl][trans-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)]

Relative stereochemistry.




RN 864171-89-1 CAPLUS
CN Benzenamine, N-[[trans-4-[[4-(4-morpholinyl)-1-piperidinyl)methyl]cyclohexyl]-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)]

Relative stereochemistry.




RN 864171-91-5 CAPLUS
CN Methanone, [trans-4-[[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-92-6 CAPLUS
CN Cyclohexanecarboxamide, 4-[[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-93-7 CAPLUS
CN 4-Morpholineethanamine, N-[[trans-4-[[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)


Relative stereochemistry.




RN 864171-99-3 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1'-methyl- (CA INDEX NAME)




RN 864172-03-2 CAPLUS
CN Ethanone, 2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-1-phenyl- (CA INDEX NAME)



RN 864172-04-3 CAPLUS
CN [1,4'-Bipiperidine]-4-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1'-methyl- (CA INDEX NAME)




Relative stereochemistry.




RN 864171-95-9 CAPLUS
CN Methanone, [trans-4-[[4-[(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-96-0 CAPLUS
CN Cyclohexanecarboxamide, 4-[[4-[(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 864171-97-1 CAPLUS
CN 4-Morpholineethanamine, N-[[trans-4-[[4-[(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)


RN 864172-05-4 CAPLUS
CN Methanone, [4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-1-piperidinyl]-4-piperidinyl- (CA INDEX NAME)



RN 864172-09-8 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[4-(4-methyl-1-piperazinyl)cyclohexyl]methyl]-, (2E)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1


CRN 864172-08-7
CMF C29 H42 N6




CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 864172-10-1 CAPLUS
CN Cyclohexanone, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)

RN 864172-11-2 CAPLUS
CN Cyclohexanol, 4-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]methyl]-, trans- (CA INDEX NAME)


Relative stereochemistry.




RN 864172-12-3 CAPLUS
CN 2H-Pyran-4-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]tetrahydro- (CA INDEX NAME)



RN 864172-13-4 CAPLUS
CN 4-Piperidinemethanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 864172-14-5 CAPLUS
CN 2H-Pyran-4-amine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]tetrahydro- (CA INDEX NAME)




RN 864172-15-6 CAPLUS

L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 864172-21-4 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[4-[[2-(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



PAGE 1-A




PAGE 2-A


RN 864172-22-5 CAPLUS
CN Methanone, [trans-4-[[[4-[[2-(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)


CN 4-Piperidinemethanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1-(1-methylethyl)- (CA INDEX NAME)




RN 864172-17-8 CAPLUS
CN 4-Piperidinemethanamine, 1-(tetrahydro-2H-pyran-4-yl)-N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



RN 864172-18-9 CAPLUS
CN 4-Piperidinemethanamine, 1-methyl-N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864172-19-0 CAPLUS
CN [1,4'-Bipiperidine]-4-methanamine, 1'-methyl-N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 864172-20-3 CAPLUS
CN 4-Piperidinemethanamine, 1-(1-methylethyl)-N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)

L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Relative stereochemistry.




RN 864172-25-8 CAPLUS
CN [1,4'-Bipiperidine]-4-methanamine, N-[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1'-methyl- (CA INDEX NAME)




RN 864172-32-7 CAPLUS
CN Methanone, [trans-4-[[[4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-33-8 CAPLUS
CN Cyclohexanecarboxamide, 4-[[4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-34-9 CAPLUS
CN Cyclohexanecarboxamide, 4-[[4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
CRN 144-62-7
CMF C2 H2 O4




RN 864172-43-0 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[cis-4-(1-pyrrolidinylmethyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-45-2 CAPLUS
CN Benzenamine, N-[cis-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-46-3 CAPLUS
CN Cyclohexanecarboxamide, N-[2-(4-morpholinyl)ethyl]-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.


RN 864172-36-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-38-3 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[cis-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-42-9 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[cis-4-(4-morpholinylmethyl)cyclohexyl]-, ethanedioate (2:1) (CA INDEX NAME)

CM 1


CRN 864172-41-8

CMF C28 H39 N5 O

Relative stereochemistry.



CM 2




RN 864172-48-5 CAPLUS
CN 4-Morpholineethanamine, N-[[cis-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 864172-47-4

CMF C29 H42 N6 O

Relative stereochemistry.



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 864172-49-6 CAPLUS
CN Methanone, [4-(4-morpholinyl)-1-piperidinyl][cis-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-50-9 CAPLUS
 CN Benzenamine,
 N-[cis-4-[[4-(4-morpholinyl)-1-piperidinyl]methyl]cyclohexyl]-
 4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-52-1 CAPLUS
 CN Benzenamine,
 N-[cis-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-54-3 CAPLUS
 CN 4-Piperidinemethanol, 1-[[[cis-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-62-3 CAPLUS
 CN Benzoic acid, 4-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 864172-69-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-71-4 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-73-6 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.




IT 137421-60-4P 137421-61-5P 864172-61-2P
 864172-62-3P 864172-69-0P 864172-71-4P
 864172-73-6P 864172-74-7P 864172-75-8P
 864172-76-9P 864172-77-0P 864172-78-1P
 864172-79-2P 864172-80-5P 864172-81-6P
 864172-82-7P 864172-90-7P 864172-91-8P
 864172-92-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Intermediate; preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists for treatment of neutrophilic inflammation)
 RN 137421-60-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine,
 2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)



RN 137421-61-5 CAPLUS
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 864172-61-2 CAPLUS
 CN Benzenamine, 3-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 864172-74-7 CAPLUS
 CN Cyclohexanecarboxylic acid,
 4-[[[4-[(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-75-8 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[4-[(2-(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 864172-76-9 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, cis- (CA INDEX NAME)


Relative stereochemistry.

L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 864172-77-0 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 864172-78-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-7-methyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)




RN 864172-79-2 CAPLUS
CN Benzenamine, 4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 864172-90-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2,5,7-trimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)

L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 864172-92-9 CAPLUS
CN 4-Piperidinecarboxamide, 1-methyl-N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



IT 864172-41-8P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists for treatment of neutrophilic inflammation)


RN 864172-41-8 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[cis-4-(4-morpholinylmethyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 864172-81-6 CAPLUS
CN Benzenamine, 4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 864172-82-7 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-90-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864172-91-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

L6 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:182661 CAPLUS
DOCUMENT NUMBER: 142:280210
TITLE: Preparation of 2-aminobenzimidazoles as TIE-2 and Raf kinase inhibitors for the treatment of tumors
INVENTOR(S): Hoelzemann, Guenter; Crassier, Helene; Ackermann, Karl-August; Staehle, Wolfgang; Jonczyk, Alfred; Rautenberg, Wilfried; Mitjans, Francesco; Rosell-Vives, Elisabet; Adan, Jaume; Soler, Marta
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019216	A1	20050303	WO 2004-EP8042	20040719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10337942	A1	20050317	DE 2003-10337942	20030818
AU 2004266797	A1	20050303	AU 2004-266797	20040719
CA 2536095	A1	20050303	CA 2004-2536095	20040719
EP 1656377	A1	20060517	EP 2004-741135	20040719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007502786	T	20070215	JP 2006-523546	20040719
US 20070021456	A1	20070125	US 2006-568626	20060216
PRIORITY APPLN. INFO.:			DE 2003-10337942	A 20030818
			WO 2004-EP8042	W 20040719

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:280210
GI



AB Title compds. I [R1 = (R4)m; R2 = (R4')p; R3 = L-Y; R4, R4' = halo, OH, CN, etc.; L = CH2, CH2CH2, O, etc.; Y = heterocycle; m, p = 0-4] and their


pharmaceutically acceptable salts were prepared. For example, condensation of 4-fluoronitrobenzene and isothiocyanate II, e.g., prepared from 5-hydroxy-2,1,3-benzothiadiazole in 3-steps, afforded aminobenzimidazole III. In TIE-2 tyrosine kinase receptor inhibition assays, 4-examples of compds. I exhibited IC50 values ranging from 0.22-0.39 μ M, e.g., the IC50 value of aminobenzimidazole III was 0.22 μ M. Compds. I are claimed to be useful for the treatment of tumors via the inhibition of TIE-2 and Raf kinases.

IT 847234-90-6P 847234-91-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminobenzimidazoles as TIE-2 and Raf kinase inhibitors for treatment of tumors)

RN 847234-90-6 CAPLUS

CN 1H-Benzimidazol-2-amine, 7-bromo-N-[4-(3H-imidazo[4,5-b]pyridin-3-ylmethyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 847234-91-7 CAPLUS

CN 1H-Benzimidazol-2-amine, 7-chloro-N-[4-(3H-imidazo[4,5-b]pyridin-3-ylmethyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)



ACCESSION NUMBER: 2000:401825 CAPLUS
 DOCUMENT NUMBER: 133:43526
 TITLE: Preparation of sulfonamides as medicines
 INVENTOR(S): Kayakiri, Hiroshi; Abe, Yoshito; Hamashima, Hitoshi; Sawada, Hitoshi; Ishibashi, Naoki; Setoi, Hiroyuki; Oku, Teruo; Yamasaki, Noritsugu; Imoto, Takafumi; Hiramura, Takahiro
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 226 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034277	A1	20000615	WO 1999-JP6748	19991201
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MM, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2352871	A1	20000615	CA 1999-2352871	19991201
EP 1136492	A1	20010926	EP 1999-973290	19991201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 2001001568	T2	20011022	TR 2001-1568	19991201
BR 9916919	A	20020115	BR 1999-16919	19991201
HU 2001004549	A2	20020429	HU 2001-4549	19991201
HU 2001004549	A3	20021228		
AU 769890	B2	20040205	AU 2000-14141	19991201
TW 577889	B	20040301	TW 1999-121089	19991202
MX 2001005374	A	20011203	MX 2001-5374	20010529
ZA 2001005493	A	20021003	ZA 2001-5493	20010703
US 6573274	B1	20030603	US 2001-856172	20010912
US 20030171396	A1	20030911	US 2003-360806	20030210
US 6890934	B2	20050510		
PRIORITY APPLN. INFO.:			JP 1998-346175	A 19981204
			JP 1998-367540	A 19981224
			JP 1999-259283	A 19990809
			WO 1999-JP6748	W 19991201
			US 2001-856172	A3 20010912

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 133:43526
 GI



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 REFERENCE COUNT: 3 (2 CITINGS)
 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT




AB Title sulfonamides [I; X = Cl, ; R2 = CH3; R3 = 7-CH3, H; R4 = 4-CH3C6H4, (E)-2-(4-pyridyl)ethylene, (CH2)4OCOCH3, 4-CH3CH2OCOCH3, 4-HOCC6H4, (CH2)4CH3, (CH2)3CH3, (CH2)2CH3, NH(CH2)4CH3; R5 = OCH(CH3)2, C6H5, OCH3, OCH2CH3, OCH2CH2CH3, OC(CH3)3, etc], or salts thereof; and drug compns. containing the same (wherein each symbol is as defined in the description) are

prepared as preventive or therapeutic agents efficacious against diseases which can be cured through decrease in blood sugar level and those which can be cured through inhibition of cGMP-PDE, relaxation of smooth muscle, bronchodilation, vasodilation, inhibition of smooth muscle fiber, or inhibition of allergy. The title compound II was prepared and tested.

IT 275384-59-3 275384-60-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of sulfonamides as medicines)


RN 275384-59-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2-chloro-4-(methylamino)phenyl]methyl]-2-methyl-N-(pentylsulfonyl)- (CA INDEX NAME)



RN 275384-60-6 CAPLUS

CN Carbamic acid, [3-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 219765-00-1P 219765-01-2P 219767-92-7P
 219767-93-8P 275382-65-5P 275382-66-6P
 275383-09-0P 275383-11-4P 275383-12-5P
 275383-13-6P 275383-14-7P 275383-15-8P
 275383-24-9P 275383-25-0P 275383-26-1P
 275383-27-2P 275383-28-3P 275383-29-4P
 275383-30-7P 275383-31-8P 275383-32-9P
 275383-33-0P 275383-34-1P 275383-35-2P
 275383-36-3P 275383-37-4P 275383-38-5P
 275383-40-9P 275383-41-0P 275383-42-1P
 275383-43-2P 275383-44-3P 275383-46-5P
 275383-48-7P 275383-50-1P 275383-52-3P
 275383-54-5P 275383-56-7P 275383-62-5P
 275383-66-9P 275384-35-5P 275384-36-6P
 275384-37-7P 275384-41-3P 275384-42-4P
 275384-56-0P 275384-57-1P 275384-58-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of sulfonamides as medicines)

RN 219765-00-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[2-chloro-4-nitrophenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 219765-01-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[4-amino-2-chlorophenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)


L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 3-[[2-chloro-4-[(cyclohexylmethyl)methylamino]phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 275383-09-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[2-chloro-4-[(1,1-dimethylethoxy)carbonyl]ethylamino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275383-11-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[2-chloro-4-[(1,1-dimethylethoxy)carbonyl]ethylamino]phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 275383-12-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[2-chloro-4-[(1,1-dimethylethoxy)carbonyl]ethylamino]phenyl]methyl]-2,7-dimethyl-, methyl ester (CA INDEX NAME)




RN 219767-92-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[2-chloro-4-[(methylpentylamino)phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 219767-93-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[2-chloro-4-[(methylpentylamino)phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 275382-65-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[2-chloro-4-[(cyclohexylmethyl)methylamino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275382-66-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,




RN 275383-13-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[2-chloro-4-[(1,1-dimethylethoxy)carbonyl]ethylamino]phenyl]methyl]-2,7-dimethyl- (CA INDEX NAME)




RN 275383-14-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[2-chloro-4-[(1,1-dimethylethoxy)carbonyl]ethylamino]phenyl]methyl]-2,7-dimethyl-, methyl ester (CA INDEX NAME)




RN 275383-15-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
 3-[[2-chloro-4-[(1,1-dimethylethoxy)carbonyl]ethylamino]phenyl]methyl]-2,7-dimethyl- (CA INDEX NAME)




RN 275383-24-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2,4-dichloro-5-nitrophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)



RN 275383-25-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2,4-dichloro-5-nitrophenyl)methyl]-2-methyl- (CA INDEX NAME)




RN 275383-26-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(5-amino-2,4-dichlorophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275383-27-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2,4-dichloro-5-(dimethylamino)phenyl)methyl]-2-methyl-, methyl ester


RN 275383-31-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(ethoxycarbonyl)amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275383-32-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(ethoxycarbonyl)amino]phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 275383-33-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(1-oxopentyl)amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275383-34-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(1-oxopentyl)amino]phenyl]methyl]-2-methyl- (CA INDEX NAME)





RN 275383-28-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2,4-dichloro-5-(dimethylamino)phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 275383-29-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-bis[(1,1-dimethylethoxy)carbonyl]amino]-2-chlorophenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275383-30-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 275383-35-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-[(butylsulfonyl)amino]-2-chlorophenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275383-36-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-[(butylsulfonyl)amino]-2-chlorophenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 275383-37-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(3,3-dimethyl-1-oxobutyl)amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275383-38-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2-chloro-4-[(3,3-dimethyl-1-oxobutyl)amino]phenyl)methyl]-2-methyl-
(CA INDEX NAME)



RN 275383-40-9 CAPLUS
CN Imidodicarbonic acid, 2-[4-[(5-bromo-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-3-chlorophenyl]-, 1,3-bis(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 275383-41-0 CAPLUS
CN Bromamic acid,
[4-[(5-bromo-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-
3-chlorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 275383-42-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]methyl]-2-
methyl-, methyl ester (CA INDEX NAME)


L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




```

RN      275383-48-7  CAPLUS
CN      3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
        3-[[2-chloro-4-[(ethoxycarbonyl)methylamino]phenyl]methyl]-2-methyl-,
        methyl ester (CA INDEX NAME)


```




RN 275383-50-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(ethoxycarbonyl)methylamino]phenyl]methyl]-2-methyl- (CA
INDEX NAME)




RN 275383-52-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(propylamino)carbonyl]amino]phenyl]methyl-2-methyl-,
methyl ester (CA INDEX NAME)




L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 275383-43-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(4-amino-2-chlorophenyl)methyl]-2-methyl-, methyl ester, hydrochloride
(1:2) (CA INDEX NAME)

 $\bullet_2 \text{HCl}$

RN 275383-44-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-([2-chloro-4-((1-methylethoxy)carbonyl)amino]phenyl)methyl)-2-methyl-
methyl ester (CA INDEX NAME)




RN 275383-46-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(1-methylethoxy)carbonyl]amino]phenyl]methyl]-2-methyl-
(CA INDEX NAME)

L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)

```

RN      275383-54-5  CAPLUS
CN      3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
(CA)    3-[[2-chloro-4-[[ (propylamino)carbonyl]amino]phenyl]methyl]-2-methyl-
        INDEX NAME)


```




```

RN      275383-56-7  CAPLUS
CN      3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
        3-[4-[(4-bromo-1-oxobutyl)amino]-2-chlorophenyl]methyl]-2-methyl-,
methyl
        ester (CA INDEX NAME)

```




RN 275383-62-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[[(2-chloroethoxy) carbonyl]amino]phenyl]methyl]-2-methyl-,
methyl ester (CA INDEX NAME)



```


RN      275383-66-9  CAPLUS
CN      3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
        3-[[2-chloro-4-[(2-hydroxyethyl)amino]phenyl]methyl]-2-methyl-
        ester (CA INDEX NAME)

```




RN 275384-35-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,

3-[[2-chloro-4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 275384-36-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,

3-[[2-chloro-4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275384-37-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-(methylamino)phenyl]methyl]-2-methyl-, methyl ester,
hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 275384-41-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(cyclohexylmethyl)amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275384-42-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(cyclohexylmethyl)amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275384-56-0 CAPLUS
CN Carbamic acid,
[4-[(5-bromo-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-3-chlorophenyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 275384-57-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[methyl[(phenylmethoxy)carbonyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 275384-58-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[methyl[(phenylmethoxy)carbonyl]amino]phenyl]methyl]-2-methyl- (CA INDEX NAME)




IT 275380-81-9P 275380-89-7P 275381-23-2P
275381-24-3P 275381-31-2P 275381-33-4P
275381-89-0P 275381-95-8P 275381-97-0P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)
(preparation of sulfonamides as medicines)
RN 275380-81-9 CAPLUS
CN Carbamic acid, [4-[[[5-[[[(butylsulfonyl)amino]carbonyl]-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-3-chlorophenyl]methyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 275380-89-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[[2-chloro-4-(methylamino)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275381-23-2 CAPLUS
CN Carbamic acid, [3-chloro-4-[[2-methyl-5-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 275381-24-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,

L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
3-[[2-chloro-4-(ethylamino)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275381-31-2 CAPLUS
CN Carbamic acid, [3-chloro-4-[[2,7-dimethyl-5-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 275381-33-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2-chloro-4-(methylamino)phenyl]methyl]-2,7-dimethyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)

L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 275381-89-0 CAPLUS
CN Carbamic acid, [4-[[5-[[[(butylsulfonyl)amino]carbonyl]-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-3-chlorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 275381-95-8 CAPLUS
CN Carbamic acid, [3-chloro-4-[[2-methyl-5-[[[(1E)-1-penten-1-ylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 275381-97-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[4-amino-2-chlorophenyl]methyl]-2-methyl-N-[(1E)-1-penten-1-ylsulfonyl]- (CA INDEX NAME)

Double bond geometry as shown.


L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



IT 275380-83-1P 275380-84-2P 275380-86-4P
275380-87-5P 275380-88-6P 275380-90-0P
275380-91-1P 275380-92-2P 275380-93-3P
275380-94-4P 275380-95-5P 275380-96-6P
275380-97-7P 275381-10-7P 275381-12-9P
275381-21-0P 275381-26-5P 275381-27-6P
275381-29-8P 275381-35-6P 275381-37-8P
275381-39-0P 275381-50-5P 275381-52-7P
275381-54-9P 275381-56-1P 275381-58-3P
275381-60-7P 275381-61-8P 275381-63-0P
275381-65-2P 275381-67-4P 275381-69-6P
275381-71-0P 275381-73-2P 275381-75-4P
275381-77-6P 275381-79-8P 275381-81-2P
275381-83-4P 275381-85-6P 275381-87-8P
275381-91-4P 275381-93-6P 275381-99-2P
275382-01-9P 275382-03-1P 275382-05-3P
275382-09-7P 275382-62-2P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides as medicines)

RN 275380-83-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, N-(butylsulfonyl)-3-[[2-chloro-4-(methylamino)phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 275380-84-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, N-(butylsulfonyl)-3-[[2-chloro-4-(ethylmethylanino)phenyl]methyl]-2-methyl- (CA INDEX NAME)


L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 275380-86-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, N-(butylsulfonyl)-3-[[2-chloro-4-(methylpropylamino)phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 275380-87-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[4-(butylmethylanino)-2-chlorophenyl]methyl]-N-(butylsulfonyl)-2-methyl- (CA INDEX NAME)




RN 275380-88-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[[2-methyl-5-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 275380-90-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[(2-chloro-4-(dimethylamino)phenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275380-91-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[(2-chloro-4-(ethylmethylanilino)phenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275380-92-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[(2-chloro-4-(methylpropylanilino)phenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275380-93-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[(4-(butylmethylanilino)-2-chlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275380-94-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[(2-chloro-4-(methylpentylanilino)phenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (CA INDEX NAME)




RN 275380-95-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[(2-chloro-4-[(cyclohexylmethyl)amino]phenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (CA INDEX NAME)




RN 275380-96-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[(2-chloro-4-[(cyclohexylmethyl)amino]phenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (CA INDEX NAME)




RN 275380-97-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[(2-chloro-4-(ethylmethylanilino)phenyl)methyl]-2,7-dimethyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275381-10-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[(2-chloro-4-[(2,2-dimethyl-1-oxopropyl)methylamino]phenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (CA INDEX NAME)




RN 275381-12-9 CAPLUS
CN Carbamic acid,
[3-chloro-4-[[2-methyl-5-[(pentylsulfonyl)amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl)methyl-1-, ethyl ester (9CI)
(CA INDEX NAME)



RN 275381-21-0 CAPLUS
CN Carbamic acid,
[3-chloro-4-[[[2-methyl-5-[[[3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]ethyl]-1,1-dimethylethyl
ester (9C1) (CA INDEX NAME)




RN 275381-26-5 CAPLUS
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide,
3-[[[2-chloro-4-(diethylamino)phenyl]methyl]-2-methyl-N-[(4-
methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275381-27-6 CAPLUS
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide,
3-[[[2-chloro-4-(ethylpentylamino)phenyl]methyl]-2-methyl-N-[(4-
methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 275381-37-8 CAPLUS
CN Carbamic acid, [3-chloro-4-[[[2,7-dimethyl-5-
[[[pentylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-
yl)methyl]phenyl]ethyl]-1,1-dimethylethyl ester (9C1) (CA INDEX NAME)




RN 275381-39-0 CAPLUS
CN Carbamic acid, [3-chloro-4-[[[2,7-dimethyl-5-[[[4-
methylphenyl)sulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-
yl)methyl]phenyl]ethyl]-1,1-dimethylethyl ester (9C1) (CA INDEX NAME)




RN 275381-50-5 CAPLUS
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide,
3-[[[2,4-dichloro-5-nitrophenyl]methyl]-2-methyl-N-(pentylsulfonyl)- (CA
INDEX NAME)




RN 275381-29-8 CAPLUS
CN Carbamic acid, [3-chloro-4-[[[2,7-dimethyl-5-
[[[pentylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-
yl)methyl]phenyl]methyl]-1,1-dimethylethyl ester (9C1) (CA INDEX NAME)




RN 275381-35-6 CAPLUS
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide,
3-[[[2-chloro-4-(methylpropylamino)phenyl]methyl]-2,7-dimethyl-N-[(4-
methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275381-52-7 CAPLUS
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide,
3-[[[2,4-dichloro-5-(dimethylamino)phenyl]methyl]-2-methyl-N-[(4-
methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 275381-54-9 CAPLUS
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide,
3-[[[2,4-dichloro-5-(dimethylamino)phenyl]methyl]-2-methyl-N-
(pentylsulfonyl)- (CA INDEX NAME)




RN 275381-56-1 CAPLUS
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide,
3-[[[2,4-dichloro-5-(dimethylamino)phenyl]methyl]-2-methyl-N-[(4-
methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275381-58-3 CAPLUS

L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[[4-[(butylsulfonyl)methylamino]-2-chlorophenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275381-60-7 CAPLUS
 CN Carbamic acid,
 [3-chloro-4-[[2-methyl-5-[[[(pentylsulfonyl)amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, 1,1-dimethylethyl ester, sodium salt (9CI) (CA INDEX NAME)




RN 275381-61-8 CAPLUS
 CN Carbamic acid,
 [3-chloro-4-[[2-methyl-5-[[[(pentylsulfonyl)amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, propyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 275381-69-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[[2-chloro-4-[[1-oxopentyl]amino]phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275381-71-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[[4-[(butylsulfonyl)amino]-2-chlorophenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275381-73-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,


L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 275381-63-0 CAPLUS
 CN Carbamic acid,
 [3-chloro-4-[[2-methyl-5-[[[(pentylsulfonyl)amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 275381-65-2 CAPLUS
 CN Carbamic acid,
 [3-chloro-4-[[2-methyl-5-[[[(pentylsulfonyl)amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 275381-67-4 CAPLUS
 CN Carbamic acid,
 [3-chloro-4-[[2-methyl-5-[[[(pentylsulfonyl)amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 3-[[2-chloro-4-[[3,3-dimethyl-1-oxobutyl]amino]phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275381-75-4 CAPLUS
 CN Carbamic acid, [3-chloro-4-[[2-methyl-5-[[[(1E)-1-pentenylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 275381-77-6 CAPLUS
 CN Carbamic acid, [4-[[5-[[[(butylsulfonyl)amino]carbonyl]-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-3-chlorophenyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 275381-79-8 CAPLUS
 CN Carbamic acid, [3-chloro-4-[[2-methyl-5-[[[(1E)-1-pentenylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
Double bond geometry as shown.



RN 275381-81-2 CAPLUS
CN Carbamic acid, [4-[[5-[[[(butylsulfonyl)amino]carbonyl]-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-3-chlorophenyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 275381-83-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[(4-amino-2-chlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (CA INDEX NAME)




RN 275381-85-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[[2-methyl-5-[[[(pentylsulfonyl)amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]-, propyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
Double bond geometry as shown.




RN 275382-01-9 CAPLUS
CN Carbamic acid, [3-chloro-4-[[2-methyl-5-[[[(1E)-1-pentenylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 275382-03-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2-chloro-4-[(propylamino)carbonyl]amino]phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 275381-87-8 CAPLUS
CN Carbamic acid, [3-chloro-4-[[2-methyl-5-[[[(pentylsulfonyl)amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 275381-91-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[(4-amino-2-chlorophenyl)methyl]-N-(butylsulfonyl)-2-methyl- (CA INDEX NAME)




RN 275381-93-6 CAPLUS
CN Carbamic acid, [4-[[5-[[[(butylsulfonyl)amino]carbonyl]-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-3-chlorophenyl]-, ethyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)

RN 275382-05-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2-chloro-4-[(methyl[(propylamino)carbonyl]amino)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 275382-09-7 CAPLUS
CN Carbamic acid, [(4-methylphenyl)sulfonyl]-, 2-[[3-chloro-4-[[2-methyl-5-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]amino]ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 275382-62-2 CAPLUS
CN Carbanic acid,
[3-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-
3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, phenylmethyl ester
(9C1) (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS
RECORD
(5 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and
2,3-dihydrobenzoxazinyl; X represents alkylene, oxygen, oxygenated lower
alkylene, etc.; and R2 represents optionally substituted aryl,
substituted
biphenyl, etc.] are prep. These compds. are useful as hypoglycemics
and have cGMP-PDE inhibitory, bronchodilating, vasodilating, smooth
muscle
cell inhibitory, and antiallergic effects, etc.
3-(2,4-Dichlorobenzyl)-2-methyl-5-(1-
pentanesulfonylcarbamoyl)benzo[b]furan at 10 mg/kg gave 71% decrease of
blood sugar in mice.
IT 219759-70-3P 219759-71-4P 219759-72-5P
219759-73-6P 219759-74-7P 219759-75-8P
219760-04-0P 219760-06-2P 219760-07-3P
219760-08-4P 219760-19-7P 219761-34-9P
219761-35-0P 219761-36-1P 219761-41-8P
219761-42-9P 219761-43-0P 219761-44-1P
219761-47-4P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic moiety-containing sulfonamide compds. as
hypoglycemics)
RN 219759-70-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[[2-chloro-4-[(phenylmethyl)amino]phenyl]methyl]-2-methyl-N-
(phenylsulfonyl)- (CA INDEX NAME)



RN 219759-71-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[[4-(butylamino)-2-chlorophenyl]methyl]-2-methyl-N-(phenylsulfonyl)-
(CA INDEX NAME)




RN 219759-72-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[[2-chloro-4-(dimethylamino)phenyl]methyl]-2-methyl-N-(phenylsulfonyl)-
(CA INDEX NAME)

L6 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1999:34900 CAPLUS
DOCUMENT NUMBER: 130:125067
TITLE: Preparation of heterocyclic moiety-containing
sulfonamide compounds as hypoglycemics
Kayakiri, Hiroshi; Abe, Yoshito; Hamashima, Hitoshi;
Sawada, Hitoshi; Mizutani, Tsuyoshi; Yamaaki,
Noritsugu; Onomura, Osamu; Nishikawa, Masahiro;
Hiramura, Takahiro; Oku, Teruo; Imoto, Takafumi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; et al.
SOURCE: PCT Int. Appl., 472 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9900372	A1	19990107	WO 1998-JP2877	19980624
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LB, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2295239	A1	19990107	CA 1998-2295239	19980624
AU 9879345	A	19990119	AU 1998-79345	19980624
AU 745081	B2	20020314		
EP 995742	A1	20000426	EP 1998-929715	19980624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 2000000486	T2	20000821	TR 2000-486	19980624
HU 2000002046	A2	20001228	HU 2000-2046	19980624
HU 2000002046	A3	20010328		
BR 9810456	A	20010925	BR 1998-10456	19980624
RU 2199532	C2	20030227	RU 2000-101813	19980624
TW 426666	B	20010321	TW 1998-110245	19980625
ZA 9805618	A	19990119	ZA 1998-5618	19980626
MX 9911779	A	20000630	MX 1999-11779	19991215
US 6348474	B1	20020219	US 2000-446110	20000214
US 20020099212	A1	20020725	US 2002-47093	20020117
US 6911469	B2	20050628		
US 20040180947	A1	20040916	US 2004-811989	20040330
PRIORITY APPLN. INFO.:			JP 1997-208295	A 19970627
			JP 1998-114718	A 19980424
			WO 1998-JP2877	W 19980624
			US 2000-446110	A3 20000214
			US 2002-47093	A3 20020117

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 130:125067
AB The title compds. R1SO2NHCOAXR2 [R1 represents alkyl, alkenyl, alkynyl,
etc.; A represents an optionally substituted polyheterocyclic group
except


L6 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 219759-73-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[[4-(acetylamino)-2-chlorophenyl]methyl]-2-methyl-N-(phenylsulfonyl)-
(CA INDEX NAME)



RN 219759-74-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[[2-chloro-4-[(methylsulfonyl)amino]phenyl]methyl]-2-methyl-N-
(phenylsulfonyl)- (CA INDEX NAME)




RN 219759-75-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[[2-chloro-4-nitrophenyl]methyl]-2-methyl-N-(phenylsulfonyl)- (CA
INDEX
NAME)




RN 219760-04-0 CAPLUS

L6 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[(2-chloro-4-nitrophenyl)methyl]-2,7-dimethyl-N-(phenylsulfonyl)- (CA INDEX NAME)




RN 219760-06-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[(2-chloro-4-nitrophenyl)methyl]-2,7-dimethyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 219760-07-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[(2-chloro-4-nitrophenyl)methyl]-2,7-dimethyl-N-[(1E)-2-phenylethenylsulfonyl]- (CA INDEX NAME)


Double bond geometry as shown.




RN 219760-08-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[(2-chloro-4-nitrophenyl)methyl]-N-[(1E)-2-(4-

L6 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)

RN 219761-35-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[[4-(benzoylamino)-2-chlorophenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 219761-36-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[[4-(benzoylmethylamino)-2-chlorophenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 219761-41-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[[2-chloro-4-[methyl(1-oxobutyl)amino]phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)

L6 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 ethenylphenyl)ethenyl]sulfonyl]-2,7-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.




RN 219760-19-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[(4-amino-2-chlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (CA INDEX NAME)




RN 219761-34-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[[2-chloro-4-[(1-oxobutyl)amino]phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




L6 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 219761-42-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[[2-chloro-4-(pentylamino)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 219761-43-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
 3-[[2-chloro-4-(methylpentylamino)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 219761-44-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[[2-chloro-4-[(phenylsulfonyl)amino]phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 219761-47-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,
3-[[2-chloro-4-[(phenylamino)carbonyl]amino]phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




IT 219765-00-1P 219765-01-2P 219765-02-3P
219765-04-5P 219765-05-6P 219765-06-7P
219765-07-8P 219765-08-9P 219765-09-0P
219765-10-3P 219765-11-4P 219765-12-5P
219765-13-6P 219766-80-0P 219766-83-3P
219767-82-5P 219767-83-6P 219767-84-7P
219767-85-8P 219767-86-9P 219767-87-0P
219767-88-1P 219767-89-2P 219767-90-5P
219767-91-6P 219767-92-7P 219767-93-8P
219767-94-9P 219767-95-0P 219768-00-0P
219768-01-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic moiety-containing sulfonamide compds. as hypoglycemics)
RN 219765-00-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-nitrophenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 219765-01-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-amino-2-chlorophenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 219765-02-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(phenylmethyl)amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 219765-04-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(phenylmethyl)amino]phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 219765-05-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-(butylamino)-2-chlorophenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 219765-06-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-(butylamino)-2-chlorophenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 219765-07-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-(dimethylamino)phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 219765-08-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-(dimethylamino)phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 219765-09-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-(acetylamino)-2-chlorophenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 219765-10-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-(acetylamino)-2-chlorophenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 219765-11-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2-chloro-4-[(methylsulfonyl)amino]phenyl)methyl]-2-methyl-, methyl
ester (CA INDEX NAME)



RN 219765-12-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2-chloro-4-[(methylsulfonyl)amino]phenyl)methyl]-2-methyl- (CA INDEX
NAME)




RN 219765-13-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2-chloro-4-nitrophenyl)methyl]-2-methyl- (CA INDEX NAME)




RN 219766-80-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2-chloro-4-nitrophenyl)methyl]-2,7-dimethyl-, methyl ester (CA INDEX
NAME)


L6 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2-chloro-4-[(1-oxobutyl)amino]phenyl)methyl]-2-methyl- (CA INDEX
NAME)




RN 219767-85-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-(benzoylamino)-2-chlorophenyl)methyl]-2-methyl- (CA INDEX NAME)




RN 219767-86-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-(benzoylmethylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl
ester (CA INDEX NAME)




RN 219767-87-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-(benzoylmethylamino)-2-chlorophenyl)methyl]-2-methyl- (CA INDEX
NAME)




RN 219766-83-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2-chloro-4-nitrophenyl)methyl]-2,7-dimethyl- (CA INDEX NAME)




RN 219767-82-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[(2-chloro-4-[(1-oxobutyl)amino]phenyl)methyl]-2-methyl-, methyl ester
(CA INDEX NAME)




RN 219767-83-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[4-(benzoylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl ester (CA
INDEX NAME)




RN 219767-84-7 CAPLUS




RN 219767-88-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[methyl(1-oxobutyl)amino]phenyl)methyl]-2-methyl-, methyl
ester (CA INDEX NAME)



RN 219767-89-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[methyl(1-oxobutyl)amino]phenyl)methyl]-2-methyl- (CA
INDEX NAME)




RN 219767-90-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-(pentylamino)phenyl)methyl]-2-methyl-, methyl ester (CA
INDEX NAME)




RN 219767-91-6 CAPLUS


L6 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-(pentylamino)phenyl]methyl]-2-methyl- (CA INDEX NAME)




RN 219767-92-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-(methylpentylamino)phenyl]methyl]-2-methyl-, methyl ester
(CA INDEX NAME)



RN 219767-93-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-(methylpentylamino)phenyl]methyl]-2-methyl- (CA INDEX NAME)



RN 219767-94-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(phenylsulfonyl)amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)



L6 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1998:487856 CAPLUS
DOCUMENT NUMBER: 129:122581
ORIGINAL REFERENCE NO.: 129:25121a
TITLE: Process for producing
2-(carboxyphenyl)-4-quinolinecarboxylic acid
compounds
INVENTOR(S): Inoue, Yoshihisa; Ebisu, Hajime; Ishida, Naomichi;
Nakamura, Norifumi; Sasaki, Jun; Okazoe, Takashi;
Morizawa, Yoshitomi; Yasuda, Arata; Wang, Shuzhong;
Ito, Tomoko
PATENT ASSIGNEE(S): The Green Cross Corporation, Japan; Asahi Glass Co.,
Ltd.
SOURCE: U.S., 12 pp., Cont.-in-part of U.S. 5,478,832.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5780634	A	19980714	US 1995-549142	19951027
JP 06016641	A	19940125	JP 1993-121979	19930426
JP 06016659	A	19940125	JP 1993-125053	19930428
US 5478832	A	19951226	US 1993-55873	19930504
JP 06080664	A	19940322	JP 1993-164222	19930608
JP 2641686	B2	19970820		
JP 08119941	A	19960514	JP 1994-264121	19941027
JP 08119942	A	19960514	JP 1994-264122	19941027
US 5665881	A	19970909	US 1995-541965	19951010
PRIORITY APPLN. INFO.:			JP 1992-143407	A 19920508
			JP 1992-176188	A 19920610
			US 1993-55873	A2 19930504
			JP 1994-264121	A 19941027
			JP 1994-264122	A 19941027
			US 1995-541965	A2 19951010

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): CASREACT 129:122581; MARPAT 129:122581
AB Quinolin-2-yl benzoic acid compds. which are useful as intermediates of quinoline compds. having angiotensin II antagonist activity prepared by decarboxylating 2-(carboxyphenyl)-4-quinolinecarboxylic acid compds. in which a carboxyl group bonded to a Ph group may be esterified, while a carboxyl group bonded to a quinoline ring is not esterified, and both rings may have one or more substituents inert to the decarboxylation reaction. Thus, 2-(2-(carboxyphenyl)-6-methyl-4-quinolinecarboxylic acid (preparation given) was heated at 180° for 1 h to give 2-(quinolin-2-yl)benzoic acid.
IT 137421-60-4P 137421-61-5P 146555-58-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for producing 2-(carboxyphenyl)-4-quinolinecarboxylic acid compds.)
RN 137421-60-4 CAPLUS

L6 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)


RN 219767-95-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(phenylsulfonyl)amino]phenyl]methyl]-2-methyl- (CA INDEX NAME)



RN 219768-00-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(phenylamino)carbonyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RN 219768-01-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,
3-[[2-chloro-4-[(phenylamino)carbonyl]amino]phenyl]methyl]-2-methyl- (CA INDEX NAME)




OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)


CN 3H-Imidazo[4,5-b]pyridine,
2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)



RN 137421-61-5 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



RN 146555-58-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-butyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1996:393882 CAPLUS
DOCUMENT NUMBER: 125:58340
ORIGINAL REFERENCE NO.: 125:11217a,11220a
TITLE: Process for producing (quinolin-2-yl)benzoic acids
INVENTOR(S): Wang, Shuzhong; Ito, Tomoko; Okazoe, Takashi;
Morizawa, Yoshitomi
PATENT ASSIGNEE(S): Asahi Glass Company Ltd., Japan; The Green Cross
Corporation
SOURCE: Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 709377	A1	19960501	EP 1995-116957	19951027
EP 709377	B1	19990929		
R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 08119941	A	19960514	JP 1994-264121	19941027
JP 08119942	A	19960514	JP 1994-264122	19941027
ES 2136782	T3	19991201	ES 1995-116957	19951027
PRIORITY APPLN. INFO.:			JP 1994-264121	A 19941027
			JP 1994-264122	A 19941027

OTHER SOURCE(S): CASREACT 125:58340; MARPAT 125:58340
GI



AB The title compds. [I; R1-R9 = H, halo, alkyl, cycloalkyl, etc.], useful as

intermediates of angiotensin II antagonists which are effective for treating hypertension, were prepared by decarboxylating a 2-carboxyphenyl-4-quinolinecarboxylic acid II with, e.g., concentrated H₂SO₄ in quinoline at 160°.

IT 137421-60-4P 137421-61-5P 146555-58-0P
146555-60-4P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (process for producing (quinolin-2-yl)benzoic acids)

RN 137421-60-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)

L6 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1995:657621 CAPLUS
DOCUMENT NUMBER: 123:55878
ORIGINAL REFERENCE NO.: 123:10063a,10066a
TITLE: Preparation of N-phenyl-4-(heterocyclymethyl)aniline and (heterocyclymethyl)dibenz[b,f]azepine
derivatives
INVENTOR(S): Mori, Shinichiro; Nakajo, Iwao; Ogasa, Takehiro;
Kasai, Masaji; Tomioka, Shinji; Ooshima, Etsuo;
Kanai, Fumihiko; Kumazawa, Toshiaki
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07061983	A	19950307	JP 1993-210419	19930825
PRIORITY APPLN. INFO.:			JP 1993-210419	19930825

OTHER SOURCE(S): CASREACT 123:55878; MARPAT 123:55878
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; V = H, (CH₂)_mP (wherein m = 1-3; P = cyano, CO₂H, tetrazolyl, cyanophenyl, carboxyphenyl, tetrazolylphenyl); X1 = X2 = H or X1X2 = CH₂, O, S, CH₂O, OCH₂, CH₂S, SCH₂, CH₂CH₂, CH:CH; R = Q, Q1, N(COR⁷)CHR⁸R⁹, Q2; R4 - R5 = H, halo, alkyl, cycloalkyl, haloalkyl, OH, CH₂OH, alkoxy, alkylamino, CO₂H, alkoxycarbonyl; Z1-Z2-Z3-Z4 = N:CHCH:CH, CH:CHCH:CH, (CH₂)₄; R7, R8 = H, alkyl, cycloalkyl; R9 = CO₂H, alkoxycarbonyl, CONH₂, CH₂OH; R10, R11 = H, alkyl; Z = N, CH] are prepared


by reaction of quaternary ammonium salts I [R = N-R1R2R3, Q3; R1 = alkyl, allyl, CH₂Ph; R2, R3 = alkyl, cycloalkyl; Y = halo, alkoxy, sulfonyloxy, aryloxy, sulfonyloxy, alkylsulfonyloxy, arylsulfonyloxy; W = H, alkyl, Ph;

Z = CH₂, S, O, (un)substituted NH; n = 1-3] with (heterocyclic) amines H-Q, H-Q1, HN(COR⁷)CHR⁸R⁹, and H-Q2. They are useful as antagonists of angiotensin II receptor for the treatment of hypertension, ischemic heart failure, kidney failure, and glaucoma (no data) or intermediates thereof. Thus, 171 g dibenz[b,f]azepine derivative (II; R = piperidino) was dissolved


in EtOAc followed by adding 46.5 mL MeI and the resulting mixture was stirred at 40° for 8 h to give a quaternary ammonium salt II (V = H, R = Q4). 2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine (36.55 g) was dissolved in DMF and after adding 5.62 g LiOH, stirred at room temperature for 15 min. To the resulting mixture were added the latter salt II (V = H,

R = Q4) and DMF and the resulting mixture was stirred at 40° for 8 h to give 45.9% a title compound II (V = H, R = Q5) which was converted into the


L6 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 137421-61-5 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



RN 146555-58-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-butyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)




RN 146555-60-4 CAPLUS
CN Benzenamine, 4-[(2-butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L6 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
N-tetrazolylmethyl deriv. II (V = Q6, R = Q5) (presumably angiotensin II receptor antagonist) in 3 steps.
IT 164520-40-5P 164520-41-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate for preparation of N-phenyl-p-(heterocyclymethyl)aniline and (heterocyclymethyl)dibenzazepine derivs. as angiotensin II receptor antagonists)
RN 164520-40-5 CAPLUS
CN Acetonitrile, 2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]phenylamino]- (CA INDEX NAME)




RN 164520-41-6 CAPLUS
CN 1H-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N-phenyl-1-(triphenylmethyl)- (CA INDEX NAME)



IT 164520-43-8P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of N-phenyl-p-(heterocyclymethyl)aniline and (heterocyclymethyl)dibenzazepine derivs. as angiotensin II receptor antagonists)

RN 164520-43-8 CAPLUS
CN 2H-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N-phenyl-1-(triphenylmethyl)- (CA INDEX NAME)

L6 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)





OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L6 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1995:573696 CAPLUS
DOCUMENT NUMBER: 122:314549
ORIGINAL REFERENCE NO.: 122:57205a, 57209a
TITLE: Preparation of [(imidazopyridinomethyl)phenoxy]phenylacetates and analogs as endothelin receptor antagonists
INVENTOR(S): Dhanoa, Daljit S.; Fitch, Kenneth J.; Veber, Daniel F.; Walsh, Thomas F.; Williams, David L., Jr.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Brit. UK Pat. Appl., 198 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2276383	A	19940928	GB 1994-5312	19940317
US 5374638	A	19941220	US 1993-34456	19930319
PRIORITY APPLN. INFO.:			US 1993-34456	A 19930319


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 122:314549
GI




AB Title compds. [I; E = bond, SOO-2(CH2)0-5, O; R = CO2H, 5-tetrazolyl(carbamoyl), P(O)(OH)2, etc.; R1 = alk(en)yl, Ph, heteroaryl, etc.; R9,R10 = H, alk(en)yl, halo, alkoxy, etc.; R11,R12 = H, alkyl, Ph, etc.; X = bond, O, CH2O, NH, etc.; Y = bond, O, NH, etc.; Z = CR4:CR4CR4:CR4, CR4:CR4CR4:N, CR4:NCR4:N, etc.; R4 = H, alkyl, halo, OH, etc.] were prepared Thus, 3,4-Cl(Me3CMe2SiO)C6H3CH2Br (preparation given) was

L6 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)

condensed with 5,7-dimethyl-2-ethylimidazo[4,5-b]pyridine and the deprotected product etherified by 2-MeC6H4CHBrCO2Me to give, after sapon., title compd. II. I had IC50 of <50nM against endothelin binding at cloned human endothelin receptors in vitro.
IT 137420-34-9P 137420-35-OP 138359-17-8P
151954-14-2P 151954-15-3P 151954-16-4P
151954-17-5P 151954-18-6P 151954-20-0P
151954-22-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(imidazopyridinomethyl)phenoxy]phenylacetates and analogs as endothelin receptor antagonists)
RN 137420-34-9 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl](1-methylethyl)amino]- (CA INDEX NAME)




RN 137420-35-0 CAPLUS
CN 2H-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N-methyl- α -phenyl- (CA INDEX NAME)




RN 138359-17-8 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl](1-methylpropyl)amino]- (CA INDEX NAME)


L6 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-14-2 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)



RN 151954-15-3 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]- (CA INDEX NAME)




RN 151954-16-4 CAPLUS
CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-17-5 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)


L6 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]- (CA INDEX NAME)




RN 151954-18-6 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino]- (CA INDEX NAME)




RN 151954-20-0 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-22-2 CAPLUS
CN Benzeneacetic acid, α -[(cyclopropylmethyl)[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




L6 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 137421-64-8 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-methyl- (CA INDEX NAME)



RN 137421-65-9 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylanino]-, methyl ester (CA INDEX NAME)




RN 137421-66-0 CAPLUS
CN Carbamic acid, ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)

IT 137421-60-4P 137421-61-5P 137421-62-6P
137421-63-7P 137421-64-8P 137421-65-9P
137421-66-0P 137421-67-1P 137421-68-2P
137421-69-3P 137421-70-6P 137421-71-7P
137421-72-8P 137421-73-9P 137421-74-0P
137421-75-1P 137421-76-2P 137421-77-3P
151954-52-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of [(imidazopyridinomethyl)phenoxy]phenylacetates and analogs as endothelin receptor antagonists)


RN 137421-60-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)



RN 137421-61-5 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 137421-62-6 CAPLUS
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137421-63-7 CAPLUS


L6 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 137421-67-1 CAPLUS
CN Benzenamine, N-ethyl-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 137421-68-2 CAPLUS
CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




RN 137421-69-3 CAPLUS
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 137421-70-6 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-propyl- (CA INDEX NAME)



RN 137421-71-7 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino]-, methyl ester (CA INDEX NAME)




RN 137421-72-8 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




RN 137421-73-9 CAPLUS


L6 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 137421-77-3 CAPLUS
CN Benzeneacetonitrile, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylanino]- (CA INDEX NAME)




RN 151954-52-8 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]-, methyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L6 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)


CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl] (2-methylpropyl)amino]-, methyl ester (CA INDEX NAME)



RN 137421-74-0 CAPLUS
CN Benzeneacetic acid, α -[(cyclopropylmethyl) 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




RN 137421-75-1 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl] (1-methylpropyl)amino]-, methyl ester (CA INDEX NAME)



RN 137421-76-2 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl] (1-methylethyl)amino]-, methyl ester (CA INDEX NAME)

L6 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN


ACCESSION NUMBER: 1995:364460 CAPLUS
DOCUMENT NUMBER: 122:187483
ORIGINAL REFERENCE NO.: 122:34347a, 34350a
TITLE: Facile, Regioselective Syntheses of N-Alkylated 2,3-Diaminopyridines and Imidazo[4,5-b]pyridines
AUTHOR(S): Khanna, Ish K.; Weier, Richard M.; Lentz, Kirk T.; Swenton, Lydia; Lankin, David C.
CORPORATE SOURCE: Department of Chemistry, G. D. Searle Co., Skokie, OK, 60077, USA
SOURCE: Journal of Organic Chemistry (1995), 60(4), 960-5
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 122:187483
AB Useful strategies are reported for the differentiation and selective synthetic manipulations of amino groups at the 2- and 3-positions of pyridines. It has been found that 2,3-diaminopyridine reacts with aldehydes under reductive amination conditions to give predominantly the N-3 alkylated products, which have been used for the regioselective synthesis of N-1 substituted imidazo[4,5-b]pyridines. Investigations using 2-formamido-3-aminopyridine (13), synthesized in two steps from 2-amino-3-nitropyridine, show it to be a versatile intermediate for the regioselective synthesis of either N-1 or N-3 substituted imidazo[4,5-b]pyridines, depending upon the conditions employed. The reductive amination of aldehydes with 13 using borane-pyridine in acetic acid affords the N-1 substituted imidazo[4,5-b]pyridines in one step, whereas reaction of 13 with alkyl halides in the presence of a suitable base (e.g., cesium carbonate) yields the N-3 substituted imidazo[4,5-b]pyridines. The generality of this synthetic methodol. is noted.
IT 161529-31-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselective syntheses of alkylated diaminopyridines and imidazopyridines)
RN 161529-31-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)


L6 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1995:67127 CAPLUS
 DOCUMENT NUMBER: 122:23206
 ORIGINAL REFERENCE NO.: 122:4393a,4396a
 TITLE: Nonpeptide angiotensin II (AII) receptor antagonists:
 N-substituted indole, dihydroindole,
 phenylaminophenylacetic acid and
 acylsulfonamide-based
 AII receptor antagonists
 AUTHOR(S): Dhanoa, D. S.; Bagley, S. W.; Chang, R. S. L.; Lotti,
 V. J.; Chen, T.; Kivlighn, S. D.; Zingaro, G.; Siegl,
 P. K. S.; Greenlee, W. J.
 CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA
 SOURCE: Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp.,
 13th (1994), Meeting Date 1993, 296-8. Editor(s):
 Hodges, Robert S.; Smith, John A. ESCOM: Leiden,
 Neth.
 CODEN: 60LXAW
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 AB The design and biol. activity of new series of angiotensin II receptor
 antagonists derived from N-substituted indole, dihydroindole,
 phenylaminophenylacetic acid and acylsulfonamide are presented.
 IT 151954-14-2 151954-15-3 151954-16-4
 151954-17-5 151954-18-6 151954-19-7
 151954-25-5 151954-29-9 151954-33-5
 151954-37-9 151954-38-0 151954-39-1
 159720-53-3
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); PRP (Properties); BIOL (Biological study)
 (structure-activity relationships of nonpeptide angiotensin II
 receptor
 antagonists)

RN 151954-14-2 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-15-3 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]methyldamino]- (CA INDEX NAME)


L6 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-25-5 CAPLUS
 CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]-2-methylphenyl]amino]- (CA INDEX NAME)



RN 151954-29-9 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino]-2-methyl- (CA
 INDEX NAME)




RN 151954-33-5 CAPLUS
 CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]amino]-3-methyl- (CA INDEX NAME)




RN 151954-37-9 CAPLUS
 CN Benzeneacetamide, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]amino]-N-(phenylsulfonyl)- (CA INDEX NAME)


L6 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-16-4 CAPLUS
 CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)



RN 151954-17-5 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]- (CA INDEX NAME)




RN 151954-18-6 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]propylamino]- (CA INDEX NAME)




RN 151954-19-7 CAPLUS
 CN Benzeneacetic acid, α -[butyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)


L6 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-38-0 CAPLUS
 CN Benzeneacetamide, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]-N-(phenylsulfonyl)-
 (CA INDEX NAME)




RN 151954-39-1 CAPLUS
 CN Benzeneacetamide, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]propylamino]-N-(phenylsulfonyl)- (CA INDEX
 NAME)




RN 159720-53-3 CAPLUS
 CN 1-Tetrazolidinemethanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]-N-methyl- α -phenyl- (CA INDEX NAME)




L6 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1994:499055 CAPLUS
 DOCUMENT NUMBER: 121:99055
 ORIGINAL REFERENCE NO.: 121:17539a,17542a
 TITLE: Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and
 acyl sulfonamides. [Erratum to document cited in CA120(5):45190z]
 AUTHOR(S): Dhanoa, Daljit S.; Bagley, Scott W.; Chang, Raymond S.
 Salah L.; Lotti, Victor J.; Chen, Tsing Bau; Kivlighn, D.; Zingaro, Gloria J.; Siegl, Peter K. S.; Patchett, Arthur A.; Greenlee, William J.
 CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA
 SOURCE: Journal of Medicinal Chemistry (1994), 37(7), 1034
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The errors were not reflected in the abstract or the index entries.
 IT 137421-62-6P 137421-72-8P 151954-46-0P
 151954-47-1P 151954-48-2P 151954-49-3P
 151954-50-6P 151954-51-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and alkylation of (Erratum))
 RN 137421-62-6 CAPLUS
 CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137421-72-8 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




RN 151954-46-0 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino]-, methyl ester (CA INDEX NAME)




RN 151954-47-1 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 151954-48-2 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3,5-bis(trifluoromethyl)-, methyl ester (CA INDEX NAME)




RN 151954-49-3 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)



RN 151954-50-6 CAPLUS
 CN Benzeneacetic acid, 2-chloro- α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester (CA INDEX NAME)




RN 151954-51-7 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3-methyl-, ethyl ester (CA INDEX NAME)




IT 137420-35-0P 138359-17-8P 151954-14-2P
 151954-15-3P 151954-16-4P 151954-17-5P
 151954-18-6P 151954-19-7P 151954-20-0P
 151954-22-2P 151954-23-3P 151954-24-4P
 151954-25-5P 151954-26-6P 151954-27-7P
 151954-28-8P 151954-29-9P 151954-30-2P
 151954-31-3P 151954-32-4P 151954-33-5P
 151954-34-6P 151954-35-7P 151954-36-8P
 151954-37-9P 151954-38-0P 151954-39-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological)


L6 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and angiotensin II antagonist activity of, structure in
 relation to (Erratum))
 RN 137420-35-0 CAPLUS
 CN 2H-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]-N-methyl- α -phenyl- (CA INDEX NAME)



RN 138359-17-8 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl] (1-methylpropyl)amino]- (CA INDEX NAME)




RN 151954-14-2 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-15-3 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]methylanino]- (CA INDEX NAME)




L6 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-20-0 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl] (2-methylpropyl)amino]- (CA INDEX NAME)



RN 151954-22-2 CAPLUS
 CN Benzeneacetic acid, α -[(cyclopropylmethyl) [4-[(2-ethyl-5,7-dimethyl-
 3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-23-3 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]-2-methylphenyl]amino]- (CA INDEX NAME)




RN 151954-24-4 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]-2-methylphenyl]methylanino]- (CA INDEX NAME)




L6 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-16-4 CAPLUS
 CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)



RN 151954-17-5 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]- (CA INDEX NAME)




RN 151954-18-6 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]propylanino]- (CA INDEX NAME)




RN 151954-19-7 CAPLUS
 CN Benzeneacetic acid, α -[butyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




L6 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-25-5 CAPLUS
 CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]-2-methylphenyl]amino]- (CA INDEX NAME)



RN 151954-26-6 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino]- (CA INDEX NAME)




RN 151954-27-7 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]-2-methylphenyl]propylanino]- (CA INDEX NAME)




RN 151954-28-8 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]-2-methylphenyl]amino]-2-methyl- (CA INDEX NAME)







RN 151954-29-9 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]-2-methyl- (CA INDEX NAME)




RN 151954-30-2 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)




RN 151954-31-3 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]-2,5-difluoro- (CA INDEX NAME)




RN 151954-32-4 CAPLUS
CN Benzeneacetic acid, 2-chloro- α -[ethyl 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RN 151954-37-9 CAPLUS
CN Benzeneacetamide, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-(phenylsulfonyl)- (CA INDEX NAME)




RN 151954-38-0 CAPLUS
CN Benzeneacetamide, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]-N-(phenylsulfonyl)- (CA INDEX NAME)




RN 151954-39-1 CAPLUS
CN Benzeneacetamide, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino]-N-(phenylsulfonyl)- (CA INDEX NAME)




RN 151954-33-5 CAPLUS
CN Benzeneacetic acid, α -[ethyl 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3-methyl- (CA INDEX NAME)




RN 151954-34-6 CAPLUS
CN Benzeneacetic acid, α -[ethyl 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro- (CA INDEX NAME)



RN 151954-35-7 CAPLUS
CN Benzeneacetic acid, α -[ethyl 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)




RN 151954-36-8 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methyl]- (CA INDEX NAME)




IT 137421-63-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deprotection of (Erratum))

RN 137421-63-7 CAPLUS
CN Carbamic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenylmethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 137421-64-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with benzaldehyde and cyanide (Erratum))


RN 137421-64-8 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-methyl- (CA INDEX NAME)




IT 137421-61-5P 151954-44-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with bromophenylacetic acid derivs. (Erratum))

RN 137421-61-5 CAPLUS


L6 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



RN 151954-44-8 CAPLUS
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methyl- (CA INDEX NAME)




IT 137421-60-4P 151954-41-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of (Erratum))
 RN 137421-60-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)




RN 151954-41-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(3-methyl-4-nitrophenyl)methyl]- (CA INDEX NAME)


L6 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 137421-73-9 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl](2-methylpropyl)amino]-, methyl ester (CA INDEX NAME)




RN 137421-75-1 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl](1-methylpropyl)amino]-, methyl ester (CA INDEX NAME)




RN 151954-52-8 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]-, methyl ester (CA INDEX NAME)

L6 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




IT 137421-65-9P 137421-68-2P 137421-71-7P
 137421-73-9P 137421-75-1P 151954-52-8P
 151954-53-9P 151954-54-0P 151954-55-1P
 151954-56-2P 151954-57-3P 151954-58-4P
 151954-59-5P 151954-60-8P 151954-61-9P
 151954-62-0P 151954-63-1P 151954-64-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and saponification of (Erratum))

RN 137421-65-9 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]-, methyl ester (CA INDEX NAME)




RN 137421-68-2 CAPLUS
 CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




RN 137421-71-7 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino]-, methyl ester (CA INDEX NAME)


L6 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-53-9 CAPLUS
 CN Benzeneacetic acid, α -[butyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




RN 151954-54-0 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]methylamino]-, methyl ester (CA INDEX NAME)




RN 151954-55-1 CAPLUS
 CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino]-, methyl ester (CA INDEX NAME)




RN 151954-56-2 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino]-, methyl ester (CA INDEX NAME)




RN 151954-57-3 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]propylamino]-, methyl ester (CA INDEX NAME)




RN 151954-58-4 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 151954-62-0 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)




RN 151954-63-1 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3,5-bis(trifluoromethyl)-, methyl ester (CA INDEX NAME)




RN 151954-64-2 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)




RN 151954-59-5 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)




RN 151954-60-8 CAPLUS
CN Benzeneacetic acid, 2-chloro- α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester (CA INDEX NAME)



RN 151954-61-9 CAPLUS
CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3-methyl-, ethyl ester (CA INDEX NAME)



IT 137421-77-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and tetrazole derivative preparation from (Erratum))
RN 137421-77-3 CAPLUS
CN Benzeneacetonitrile, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]- (CA INDEX NAME)



L6 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1994:426465 CAPLUS
DOCUMENT NUMBER: 121:26465

ORIGINAL REFERENCE NO.: 121:4633a,4636a

TITLE: Benzofuran based non-peptide antagonists of

angiotensin II related to GR117289; Part IV:
Imidazopyridinylbenzofurans

AUTHOR(S): Judd, D. B.; Cardwell, K. S.; Panchal, T. A.; Jack,
T.

I.; Pass, M.; Hubbard, T.; Dean, A. W.; Butt, A. U.;
Hobson, J. E.; et al.


CORPORATE SOURCE: Glaxo Group Res., Ware/Herts, SG12 ODP, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (1994),
4(5),

725-8
CODEN: BMCLE8; ISSN: 0960-894X

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The identification of a series of imidazopyridinylbenzofurans (I, R1 = H, Me, CO2H, or CH2OH) as potent, non-peptide antagonists of angiotensin II is described. Several of these compds. decrease the blood pressure in the renal artery ligated rat model of hypertension after oral administration. (I, R1 = Me or CH2OH) have high bioavailability and metabolic stability and low plasma clearance in rats.


IT 155930-55-5 155930-56-6
RL: BIOL (Biological study)
(antihypertensive and angiotensin II receptor antagonist activities

and pharmacokinetics of)

RN 155930-55-5 CAPLUS


CN Methanesulfonamide, N-[3-bromo-5-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-6-benzofuranyl]-1,1,1-trifluoro- (CA INDEX NAME)

L6 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 155930-56-6 CAPLUS

CN Methanesulfonamide, N-[3-bromo-5-[[2-ethyl-5-(hydroxymethyl)-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-6-benzofuranyl]-1,1,1-trifluoro- (CA INDEX NAME)



IT 155930-57-7 155930-58-8

RL: BIOL (Biological study)
(antihypertensive and angiotensin II receptor antagonist activities


of)

RN 155930-57-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-5-carboxylic acid,


3-[[3-bromo-6-[(trifluoromethyl)sulfonyl]amino]-5-benzofuranyl)methyl]-2-ethyl-7-methyl- (CA INDEX NAME)

L6 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 155930-58-8 CAPLUS

CN Methanesulfonamide, N-[3-bromo-5-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-6-benzofuranyl]-1,1,1-trifluoro- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS
RECORD (5 CITINGS)

L6 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1994:260550 CAPLUS
DOCUMENT NUMBER: 120:260550

ORIGINAL REFERENCE NO.: 120:45817a,45820a

TITLE: Acidic phenols: a new class of potent nonpeptide

angiotensin II receptor antagonists

AUTHOR(S): Kim, Dooseop; Mantlo, Nathan B.; Tata, J. R.; Fitch,
K.; Dhanoa, D.; Owens, K.; Lavoise, D.; Siegl, P. K.
S.; Chang, R. S. L.; et al.


CORPORATE SOURCE: Dep. Expl., Merck Res. Lab., Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1994),
4(1),

207-12
CODEN: BMCLE8; ISSN: 0960-894X

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB A series of imidazo[4,5-b]pyridine-based acidic phenols are exemplified
as

novel non-peptide AII receptor antagonists. O,o'-substituents which affect the acidity of the phenolic portion dramatically impact the activity of the compds. The most potent antagonist in this series (I, IC50 = 5nM, rabbit aorta) exhibited good in vivo potency after both i.v. and oral administration to conscious rats.


IT 154152-14-4P 154152-15-5P 154152-16-6P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and angiotensin II antagonist activity of)


RN 154152-14-4 CAPLUS

CN Phenol, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-nitro- (CA INDEX NAME)




RN 154152-15-5 CAPLUS


L6 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 CN Phenol, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-nitro-6-(2-propen-1-yl)- (CA INDEX NAME)



RN 154152-16-6 CAPLUS
 CN Phenol, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-iodo-6-nitro- (CA INDEX NAME)



IT 154152-28-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and dealkylation of)
 RN 154152-28-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[[3-nitro-4-(2-propen-1-yloxy)phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 Incorporation of the acyl sulfonamide (CONHSO₂-Ph) for the CO₂H of IV not only enhanced the AT₁ potency but also effected a marked increase in the AT₂ potency of VII (AT₂ IC₅₀ = 0.74 μM of VI vs 0.2 μM of VII) and made it the most potent AT₂ antagonist in this study. Replacement of the CO₂H of with the bioisostere tetrazole resulted in III (AT₁ IC₅₀ = 15 nM) with a 2-fold loss in the AT₁ and a complete loss in the AT₂ binding affinity. (Phenylamino)phenylacetic acid IV demonstrated good oral activity in AII-infused conscious normotensive rats at an oral dose of

1.0 mg/kg by inhibiting the pressor response for >6 h. Acyl sulfonamides VII-IX displayed excellent in vivo activity by blocking the AII-induced pressor response for >6 h after oral administration in conscious rats at


a 3.0 mg/kg dose level. Both acyl sulfonamides VII and IX exhibited superior in vivo activity in rats compared to that of (phenylamino)phenylacetic acid IV.

IT 137421-62-6P 137421-72-8P 151954-46-0P
 151954-47-1P 151954-48-2P 151954-49-3P
 151954-50-6P 151954-51-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and alkylation of)

RN 137421-62-6 CAPLUS
 CN Carbanic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137421-72-8 CAPLUS
 CN Benzeneacetic acid, α-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




RN 151954-46-0 CAPLUS
 CN Benzeneacetic acid, α-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)

L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1994:45190 CAPLUS
 DOCUMENT NUMBER: 120:45190
 ORIGINAL REFERENCE NO.: 120:8047a,8050a
 TITLE: Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and sulfonamides
 AUTHOR(S): Dhanoa, Daljit S.; Bagley, Scott W.; Chang, Raymond S.
 L.; Lotti, Victor J.; Chen, Tsing Bau; Kivlighn, Salah
 D.; Zingaro, Gloria J.; Siegl, Peter K. S.; Patchett, Arthur A.; Greenlee, William J.
 CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA
 SOURCE: Journal of Medicinal Chemistry (1993), 36(26), 4239-49
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 120:45190
 GI




AB The design, synthesis, and biol. activity of a new class of highly potent non-peptide AII receptor antagonists derived from N-substituted (phenylamino)phenylacetic acid and acyl sulfonamides which exhibit a high selectivity for the AT₁ receptor are described. A series of N-substituted (phenylamino)phenylacetic acids (I) and acyl sulfonamides (II) and a tetrazole derivative (III) were synthesized and evaluated in the in vitro AT₁ (rabbit aorta) and AT₂ (rat midbrain) binding assay. The (phenylamino)phenylacetic acids I (R = Et) (IV) (AT₁ IC₅₀ = 4 nM, AT₂ IC₅₀ = 0.74 μM), I (R = allyl) (V) (AT₁ IC₅₀ = 5.3 nM, AT₂ IC₅₀ = 0.49 μM), and I (R = Pr) (VI) (AT₁ IC₅₀ = 5.3 nM, AT₂ IC₅₀ = 0.56 μM) were found to be the most potent AT₁-selective AII antagonists in the acid series. Incorporation of various substituents in the central and bottom Ph rings led to a decrease in the AT₁ and AT₂ binding affinity of the resulting compds. Replacement of the carboxylic acid (CO₂H) in IV, V, and VI with the bioisostere acyl sulfonamide (CONHSO₂Ph) resulted in a (5-7)-fold increase in the AT₁ potency of II (R = Et) (VII) (AT₁ IC₅₀ = 0.9 nM, AT₂ IC₅₀ = 0.2 μM), II (R = allyl) (VIII) (AT₁ IC₅₀ = 1 nM, AT₂ IC₅₀ = 2.9 μM), and II (R = Pr) (IX) (AT₁ IC₅₀ = 0.8 nM, AT₂ IC₅₀ = 0.42 μM) and yielded acyl sulfonamides with subnanomolar AT₁ activity.


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 151954-47-1 CAPLUS
 CN Benzeneacetic acid, α-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 151954-48-2 CAPLUS
 CN Benzeneacetic acid, α-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3,5-bis(trifluoromethyl)-, methyl ester (CA INDEX NAME)




RN 151954-49-3 CAPLUS
 CN Benzeneacetic acid, α-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 151954-50-6 CAPLUS
CN Benzeneacetic acid, 2-chloro- α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester (CA INDEX NAME)




RN 151954-51-7 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3-methyl-, ethyl ester (CA INDEX NAME)




IT 137420-35-0P 138359-17-8P 151954-14-2P
151954-15-3P 151954-16-4P 151954-17-5P
151954-18-6P 151954-19-7P 151954-20-0P
151954-22-2P 151954-23-3P 151954-24-4P
151954-25-5P 151954-26-6P 151954-27-7P
151954-28-8P 151954-29-9P 151954-30-2P
151954-31-3P 151954-32-4P 151954-33-5P
151954-34-6P 151954-35-7P 151954-36-8P
151954-37-9P 151954-38-0P 151954-39-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preph. and angiotensin II antagonist activity of, structure in relation to)
RN 137420-35-0 CAPLUS
CN 2H-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N-methyl- α -phenyl- (CA INDEX NAME)



RN 138359-17-8 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl] (1-methylpropyl)amino]- (CA INDEX NAME)




RN 151954-14-2 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-15-3 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]- (CA INDEX NAME)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-16-4 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)



RN 151954-17-5 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]- (CA INDEX NAME)




RN 151954-18-6 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino]- (CA INDEX NAME)




RN 151954-19-7 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-20-0 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl] (2-methylpropyl)amino]- (CA INDEX NAME)



RN 151954-22-2 CAPLUS
CN Benzeneacetic acid, α -[[4-[(cyclopropylmethyl) [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-23-3 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino]- (CA INDEX NAME)




RN 151954-24-4 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]methylamino]- (CA INDEX NAME)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-25-5 CAPLUS
CN Benzeneacetic acid, α-[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino]- (CA INDEX NAME)



RN 151954-26-6 CAPLUS
CN Benzeneacetic acid, α-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino]- (CA INDEX NAME)




RN 151954-27-7 CAPLUS
CN Benzeneacetic acid, α-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]propylamino]- (CA INDEX NAME)




RN 151954-28-8 CAPLUS
CN Benzeneacetic acid, α-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino]-2-methyl- (CA INDEX NAME)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-33-5 CAPLUS
CN Benzeneacetic acid, α-[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3-methyl- (CA INDEX NAME)



RN 151954-34-6 CAPLUS
CN Benzeneacetic acid, α-[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro- (CA INDEX NAME)




RN 151954-35-7 CAPLUS
CN Benzeneacetic acid, α-[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)




RN 151954-36-9 CAPLUS
CN Benzeneacetic acid, α-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino]-N-(phenylsulfonyl)- (CA INDEX NAME)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 151954-29-9 CAPLUS
CN Benzeneacetic acid, α-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino]-2-methyl- (CA INDEX NAME)



RN 151954-30-2 CAPLUS
CN Benzeneacetic acid, α-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)




RN 151954-31-3 CAPLUS
CN Benzeneacetic acid, α-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]-2,5-difluoro- (CA INDEX NAME)




RN 151954-32-4 CAPLUS
CN Benzeneacetic acid, 2-chloro-α-[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]-2,5-difluoro- (CA INDEX NAME)




RN 151954-37-9 CAPLUS
CN Benzeneacetamide, α-[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-(phenylsulfonyl)- (CA INDEX NAME)




RN 151954-38-0 CAPLUS
CN Benzeneacetamide, α-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]-N-(phenylsulfonyl)- (CA INDEX NAME)




RN 151954-39-1 CAPLUS
CN Benzeneacetamide, α-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino]-N-(phenylsulfonyl)- (CA INDEX NAME)




IT 137420-35-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and angiotensin II antagonist activity of, structure in relation to)
 RN 137420-35-0 CAPLUS
 CN 2H-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N-methyl- α -phenyl- (CA INDEX NAME)




IT 137421-63-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deprotection of)
 RN 137421-63-7 CAPLUS
 CN Carbanic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 137421-64-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, with benzaldehyde and cyanide)
 RN 137421-64-8 CAPLUS
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-methyl- (CA INDEX NAME)




RN 151954-41-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(3-methyl-4-nitrophenyl)methyl]- (CA INDEX NAME)




IT 137421-65-9P 137421-68-2P 137421-71-7P
 137421-73-9P 137421-75-1P 151954-52-8P
 151954-53-9P 151954-54-0P 151954-55-1P
 151954-56-2P 151954-57-3P 151954-58-4P
 151954-59-5P 151954-60-8P 151954-61-9P
 151954-62-0P 151954-63-1P 151954-64-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and saponification of)
 RN 137421-65-9 CAPLUS
 CN Benzenecetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylanino]-, methyl ester (CA INDEX NAME)




RN 137421-68-2 CAPLUS
 CN Benzenecetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




IT 137421-61-5P 151954-44-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, with bromophenylacetic acid derivs.)
 RN 137421-61-5 CAPLUS
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 151954-44-8 CAPLUS
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methyl- (CA INDEX NAME)




IT 137421-60-4P 151954-41-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RN 137421-60-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)




RN 137421-71-7 CAPLUS
 CN Benzenecetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylanino]-, methyl ester (CA INDEX NAME)



RN 137421-73-9 CAPLUS
 CN Benzenecetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl] (2-methylpropyl)amino]-, methyl ester (CA INDEX NAME)




RN 137421-75-1 CAPLUS
 CN Benzenecetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl] (1-methylpropyl)amino]-, methyl ester (CA INDEX NAME)




L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)


RN 151954-52-8 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]-, methyl ester (CA INDEX NAME)



RN 151954-53-9 CAPLUS
CN Benzeneacetic acid, α -[butyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




RN 151954-54-0 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]methylamino]-, methyl ester (CA INDEX NAME)




RN 151954-55-1 CAPLUS
CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino]-, methyl ester (CA INDEX NAME)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 151954-59-5 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)




RN 151954-60-8 CAPLUS
CN Benzeneacetic acid, 2-chloro- α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester (CA INDEX NAME)




RN 151954-61-9 CAPLUS
CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3-methyl-, ethyl ester (CA INDEX NAME)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 151954-56-2 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino]-, methyl ester (CA INDEX NAME)




RN 151954-57-3 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]propylamino]-, methyl ester (CA INDEX NAME)




RN 151954-58-4 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino]-2-methyl-, ethyl ester (CA INDEX NAME)


L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 151954-62-0 CAPLUS
CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)




RN 151954-63-1 CAPLUS
CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3,5-bis(trifluoromethyl)-, methyl ester (CA INDEX NAME)




RN 151954-64-2 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)

L6 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



IT 137421-77-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and tetrazole derivative preparation from)
 RN 137421-77-3 CAPLUS
 CN Benzeneacetonitrile, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]- (CA INDEX NAME)




OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

L6 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1993:671155 CAPLUS
 DOCUMENT NUMBER: 119:271155
 ORIGINAL REFERENCE NO.: 119:48529a,48532a
 TITLE: Preparation of N-[(α -carboxyalkoxy)benzyl]benzimidazoles and analogs as angiotensin II antagonists
 INVENTOR(S): Riez, Uwe; Narr, Berthold; Haeu, Norbert; Wienen, Wolfgang; Van Meel, Jacques; Entzeroth, Michael
 PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Germany
 SOURCE: Ger. Offen., 57 pp. Addn. to Ger. Offen. 4,123,341.
 CODEN: GWXXBK
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4142366	A1	19930624	DE 1991-4142366	19911220
DE 4123341	A1	19930121	DE 1991-4123341	19910715
PRIORITY APPLN. INFO.:			DE 1991-4123341	19910715

OTHER SOURCE(S): MARPAT 119:271155
 GI




AB RaAZBCRbRc(CH2)nRd [A = CH2, CH2CH2, CHMe, etc.; B = O, CH2, NH, NMe, etc.; Ra = substituted (benz)imidazolo, -oxoquinazolino, -quinolin-4-yloxy, etc.; Rb = CO2H, tetrazolyl, alkylsulfonylearboxamoyl, etc.; Rc = H, (ar)alkyl, aryl, CO2H, alkoxy-carbonyl; Rd = (cyclo)alkyl, alkenyl, Ph, naphthyl, heteroaryl; Z = (substituted) 1,4-phenylene; n = 0 or 1] were prepared Thus, 4-(BrH2C)C6H4OCHPhCO2Et (preparation given)
 was


condensed with 2-propyl-4-methylbenzimidazole to give, after sapon, title compound I (R = H). I (R = 1-methylbenzimidazol-2-yl) had IC50 of 4 nM against angiotensin II binding at rat lung tissue prepn in vitro.

IT 150478-13-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as angiotensin II antagonist)
 RN 150478-13-0 CAPLUS
 CN Phosphonic acid, [[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]phenylmethyl]-, monoethyl ester, monosodium salt (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




IT 150479-18-8
 RL: RCT (Reactant); RACT (Reactant or reagent) (reaction of, in preparation of angiotensin II antagonist)
 RN 150479-18-8 CAPLUS
 CN Phosphonic acid, [[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]phenylmethyl]-, diethyl ester (9CI) (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L6 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1993:449306 CAPLUS
 DOCUMENT NUMBER: 119:49306
 ORIGINAL REFERENCE NO.: 119:8945a,8948a
 TITLE: Nonpeptide angiotensin II receptor antagonists. 1. Synthesis and in vitro structure-activity relationships of 4-[[[(1H-pyrrol-1-ylacetyl)amino]phenyl]methyl]imidazole derivatives as angiotensin II receptor antagonists
 AUTHOR(S): Sircar, Ila; Winters, R. Thomas; Quin, John, III; Lu, Gina H.; Major, Terry C.; Panek, Robert L.
 CORPORATE SOURCE: Dep. Chem., Parke-Davis Pharm. Res., Ann Arbor, MI, 48105, USA
 SOURCE: Journal of Medicinal Chemistry (1993), 36(12), 1735-45
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 119:49306
 GI




AB A novel series of non-biphenyltetrazole angiotensin II receptor antagonists which contain a 1H-pyrrol-1-ylacetyl residue in place of the benzoyl residue in EXP 6803 have been developed. The receptor binding activity of several members of this new series was in the 10-8 M range, which was better than that of EXP 6803. Introduction of a carboxylic acid moiety at the 2-position of the pyrrole ring enhanced the in vitro binding affinity at the receptor by 10-fold. Comps. containing an acetic acid I (n = 1) or a propionic acid residue I (n = 2) at the 5-position of the imidazole were more potent than the carboxylic acid analog I (n = 0).

The binding IC50 of the most potent compound I (n = 2) was 22 nM. I in their best fit conformations were manually overlaid on that of the template conformation of EXP 6803 and EXP 6823, resp. The synthesis and structure-activity relationship data are described.
 IT 137421-61-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and acylation of, with pyrrolealkanoic acids)
 RN 137421-61-5 CAPLUS
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




IT 142219-21-4P 142219-26-9P 148550-05-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and angiotensin II receptor antagonist activity of)
 RN 142219-21-4 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 142219-26-9 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148550-05-4 CAPLUS
 CN 1H-Pyrrole-1-acetic acid, 2-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]-α-(phenylmethyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 137421-60-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RN 137421-60-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)

ACCESSION NUMBER: 1993:147562 CAPLUS
 DOCUMENT NUMBER: 118:147562
 ORIGINAL REFERENCE NO.: 118:25383a, 25386a
 TITLE: Preparation of imidazo[4,5-b]pyridine derivatives as angiotensin II receptor blockers
 INVENTOR(S): Taguchi, Minoru; Muto, Masaru; Ota, Tomoki; Hatayama, Katsuo
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04300882	A	19921023	JP 1991-133715	19910327

PRIORITY APPLN. INFO.: JP 1991-133715 19910327

OTHER SOURCE(S): MARPAT 118:147562
 GI




AB The title derivs. I [R = C1-7 alkyl(thio); R1 = carboxy, sulfoxyl; X = H, halo] and their salts, useful for treatment of hypertension and heart failure, are prepared A solution of 1.00 g 2-butylimidazo[4,5-b]pyridine (preparation given) in DMF was stirred with NaH and then treated with


1.85 g 4-nitrobenzyl bromide at 0° for 5 h to give 0.78 g 2-butyl-3-[(4-nitrobenzyl)imidazo[4,5-b]pyridine, 1.03 g of which was heated with Fe and AcOH in MeOH under reflux for 6 h to give 0.84 g 2-butyl-3-[(4-aminobenzyl)imidazo[4,5-b]pyridine (II). Then, 3.0 g II was treated with 2.6 g 2-sulfobenzoic anhydride in CH2Cl2 at room temperature overnight to give 3.4 g I (R = Bu, R1 = SO3H, X = H), which inhibited angiotensin II binding in rat adrenal cortical microsomes with an IC50 of 0.034 μM.

IT 146555-60-4P 146555-61-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and amidation of)

RN 146555-60-4 CAPLUS
 CN Benzenamine, 4-[(2-butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 146555-61-5 CAPLUS
 CN Benzenamine, 4-[(2-propyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




IT 146555-58-0P 146555-59-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)

RN 146555-58-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-butyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)




RN 146555-59-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-nitrophenyl)methyl]-2-propyl- (CA INDEX NAME)




IT 146555-62-6P 146555-63-7P 146555-64-8P
 146555-65-9P 146555-66-0P 146555-67-1P
 146555-68-2P 146555-69-3P 146555-70-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as angiotensin II receptor blocker)
 RN 146555-62-6 CAPLUS
 CN Benzoic acid, 2-[[[4-[(2-butyl-3H-imidazo[4,5-b]pyridin-3-


L6 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)
yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 146555-63-7 CAPLUS
CN Benzoic acid, 3,6-dichloro-2-[[[4-[(2-propyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 146555-64-8 CAPLUS
CN Benzoic acid, 2-[[[4-[(2-(propylthio)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 146555-65-9 CAPLUS
CN Benzoic acid, 2-[[[4-[(2-butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]-3,6-dichloro- (CA INDEX NAME)



RN 146555-66-0 CAPLUS

L6 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)


RN 146555-70-6 CAPLUS
CN Benzenesulfonic acid, 2-[[[4-[(2-(ethylthio)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L6 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)


CN Benzoic acid, 3,6-dichloro-2-[[[4-[(2-(ethylthio)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 146555-67-1 CAPLUS
CN Benzenesulfonic acid, 2-[[[4-[(2-butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 146555-68-2 CAPLUS
CN Benzenesulfonic acid, 2-[[[4-[(2-propyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 146555-69-3 CAPLUS
CN Benzenesulfonic acid, 2-[[[4-[(2-(propylthio)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)





L6 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN

ACCESSION NUMBER: 1992:469865 CAPLUS
DOCUMENT NUMBER: 117:69865
ORIGINAL REFERENCE NO.: 117:12295a,12298a
TITLE: Preparation of (imidazolylmethyl)acetanilide derivatives as angiotensin II antagonists
INVENTOR(S): Sircar, Ila
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9206081	A1	19920416	WO 1991-US6798	19910919
W: AU, CA, CS, FI, HU, JP, KR, NO, SU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
US 5242939	A	19930907	US 1991-757021	19910913
AU 9186598	A	19920428	AU 1991-86598	19910919
PRIORITY APPLN. INFO.:			US 1990-590626	A 19900928
			US 1991-757021	A 19910913
			WO 1991-US6798	A 19910919


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 117:69865
GI



AB Title compds. I [X, X1 = C, N; R, R1 = H, halo, C1-6 alkyl, alkoxy, carbonyl, carboxyalkyl, trihalomethyl, perfluoroethyl, cyano, CH2CN, alkoxy, methyl, hydroxymethyl, CO2H, etc.; R1 is absent when X = N; RR1 = 5- or 6-membered (substituted) (hetero)aryl ring when X = C; R, R1 = vinyl, C2-10 alkynyl, aryl, heteroaryl, etc., when X = C; R2 = Pr, Bu,


L6 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
cycloalkyl, allyl, propargyl, Sme, Cme, etc.; R3 = CR4R4R6; R4 = H,.
C1-6
alkyl, (substituted) aryl, etc., when R5 = H; R6 = cyano, CO2H, tetrazolyl, etc.; or R5R6 = CO, C(OH) were prepd. as angiotensin II antagonists useful as antihypertensives. Thus, L-phenylalanine was cyclocondensed with Me 2,5-dimethoxytetrahydrofuran-2-carboxylate to give 2-(methoxycarbonyl)- α -phenylmethyl-1H-pyrrole-1-acetic acid. This was coupled with
1-[(4-aminophenyl)methyl]-2-butyl-4-chloro-1H-imidazole-5-methanol (prepn. given) in the presence of 1-hydroxybenzotriazole and DCC to give title compd. (S)-II. The latter was effective at 0.21 μ M in vitro in inhibiting binding of 3H-angiotensin II to rat liver membranes.
IT 142219-21-4P 142219-26-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as angiotensin II antagonist)
RN 142219-21-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, (S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.



RN 142219-26-9 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, (S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.



IT 137421-60-4P 137421-61-5P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as intermediate for angiotensin II antagonists)
RN 137421-60-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)


L6 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1992:426566 CAPLUS
DOCUMENT NUMBER: 117:26566
ORIGINAL REFERENCE NO.: 117:4803a,4806a
TITLE: Preparation of [(tetrazolyl)pyrrolyl]benzyl]imidazopyridines and related compounds as angiotensin II antagonists
INVENTOR(S): Oku, Teruo; Setoi, Hiroyuki; Kayakiri, Hiroshi; Sato, Shigeki; Inoue, Takayuki; Saitoh, Yuki; Kuroda, Akio; Tanaka, Hirokazu
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 84 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 480204	A1	19920415	EP 1991-115644	19910914
EP 480204	B1	19960320		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5210092	A	19930511	US 1991-748954	19910823
AU 9183454	A	19920402	AU 1991-83454	19910830
AU 650473	B2	19940623		
FI 9104163	A	19920326	FI 1991-4163	19910904
ZA 9107228	A	19920729	ZA 1991-7228	19910911
AT 135701	T	19960415	AT 1991-115644	19910914
CN 1059723	A	19920325	CN 1991-109182	19910924
CA 2052125	A1	19920326	CA 1991-2052125	19910924
NO 9103750	A	19920326	NO 1991-3750	19910924
HU 59404	A2	19920528	HU 1991-3052	19910924
JP 04288075	A	19921013	JP 1991-317589	19910924
PRIORITY APPLN. INFO.:			GB 1990-20838	A 19900925
			GB 1990-23467	A 19901029
			GB 1990-28216	A 19901231
			GB 1991-3874	A 19910225
			GB 1991-6956	A 19910403
			GB 1991-7231	A 19910405
			GB 1991-12803	A 19910614


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 117:26566
GI For diagram(s), see printed CA Issue.
AB Title compds. [I; R1 = H, halo, NO2, alkyl, alkoxy, (acyl)amino; R2-R4 = H, halo, NO2, cyano, alkyl, alkenyl, alkylthio, haloalkyl, oxoalkyl, hydroxyalkyl, (esterified) carboxy; R2R3 = CH:CHCH:CH; R5 = H, protecting group; A = alkylene; Q, X = CH, N; Y = NH, O, S; Z = atoms to complete a (substituted) (condensed) imidazolyl], were prepared. Thus, 3-[4-[4-bromo-2-cyano-1-pyrrolyl]benzyl]-2-butyl-7-methyl-3H-imidazo[4,5-b]pyridine was heated with Me3SnN3 in xylene to give title compound II.

II

L6 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 137421-61-5 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
REFERENCE COUNT: 2 (3 CITINGS)
THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L6 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
inhibited angiotensin II in guinea pig ileal strips with IC50 = 1.7 + 10-9M.
IT 142014-19-5P 142014-23-1P 142014-24-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as angiotensin II antagonist)
RN 142014-19-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-butyl-7-methyl-3-[[3-nitro-4-[2-(2H-tetrazol-5-yl)-1H-pyrrol-1-yl]phenyl]methyl]- (CA INDEX NAME)




RN 142014-23-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-butyl-7-methyl-3-[[3-nitro-4-[2-(2H-tetrazol-5-yl)-1H-pyrrol-1-yl]phenyl]methyl]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 142014-24-2 CAPLUS
CN Acetamide, N-[5-[(2-butyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-[2-(2H-tetrazol-5-yl)-1H-pyrrol-1-yl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)




● Na

IT 142017-07-0P 142045-36-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for angiotensin II antagonists)
 RN 142017-07-0 CAPLUS
 CN Benzenamine,
 5-[(2-butyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-
 [2-(2H-tetrazol-5-yl)-1H-pyrrol-1-yl]- (CA INDEX NAME)



RN 142045-36-1 CAPLUS
 CN 1H-Pyrrole-2-carbonitrile, 1-[4-[(2-butyl-7-methyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]-2-nitrophenyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS
 RECORD (12 CITINGS)

L6 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1991:656165 CAPLUS
 DOCUMENT NUMBER: 115:256165
 ORIGINAL REFERENCE NO.: 115:43561a,43564a
 TITLE: Preparation of N-benzylated imidazopyridines and
 benzimidazoles as angiotensin II antagonists
 INVENTOR(S): Greenlee, William J.; Patchett, Arthur A.; Hangauer,
 David; Walsh, Thomas; Fitch, Kenneth J.; Rivero,
 Ralph
 PATENT ASSIGNEE(S): A.; Dhanoa, Daljit S.
 SOURCE: Merck and Co., Inc., USA
 PCT Int. Appl., 401 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9111999	A1	19910822	WO 1991-US957	19910211
W: CA, JP				
RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2075627	A1	19910814	CA 1991-2075627	19910211
CA 2075637	A1	19910814	CA 1991-2075637	19910211
EP 517812	A1	19921216	EP 1991-905733	19910211
R: CH, DE, FR, GB, IT, LI, NL				
JP 05504969	T	19930729	JP 1991-505964	19910211
US 5240938	A	19930831	US 1991-744557	19910813
US 5264439	A	19931123	US 1991-744138	19910813
US 5449682	A	19950912	US 1993-61975	19930517
PRIORITY APPLN. INFO.:			US 1990-479786	A 19900213
			WO 1991-US957	W 19910211
			US 1991-671551	B2 19910319
			US 1991-671552	B2 19910319
			US 1991-744557	A3 19910813

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 115:256165
 GI




AB Title comps. [I; R1 = (substituted) alkyl, alkenyl, alkynyl,
 (hetero)aryl, perfluoroalkyl; R9, R10 = H, (cycloalkyl)alkyl, alkenyl,
 alkynyl, halo, alkoxy, perfluoroalkyl, (alkyl)cycloalkyl, aryl, adjacent
 R9R10 = CH:CHCH:CH; R11, R12 = H, (substituted) alkyl, aryl, arylalkyl,
 cycloalkyl; B = bond, Son(CH2)s, O; n = 0-2; s = 0-5; X = O, Son, imino,
 CH2O, CH2, CH2CH2, bond SonCH2, etc.; Y = bond, Son imino, CH2; Z = CO2H,
 alkoxy carbonyl, tetrazol-5-yl, arylsulfonyl carbamoyl, P(O)(OH)2, etc.;
 A1-A2-A3-A4-A5 = moieties to complete (substituted) benzene or
 heterocyclic (e.g., pyridine rings), were prepared as antihypertensives,
 nootropics, anxiolytics, and antidepressants (no data). Thus,
 2-butylbenzimidazole and 4-(PhCH2O)C6H4Cl were condensed to give 96%
 N-benzylated product, which was hydrogenolyzed (83%) followed by
 condensation with BrCHPhCO2Me (17%) and saponification (30%) to give
 title compound


IT 137420-34-9P 137420-35-0P 138359-17-8P
 151954-14-2P 151954-15-3P 151954-16-4P
 151954-17-5P 151954-18-6P 151954-20-0P
 151954-22-2P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as angiotensin II antagonist)
 RN 137420-34-9 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl](1-methylethyl)amino]- (CA INDEX NAME)




RN 137420-35-0 CAPLUS
 CN 2H-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]-N-methyl- α -phenyl- (CA INDEX NAME)




RN 138359-17-8 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl](1-methylpropyl)amino]- (CA INDEX NAME)



RN 151954-14-2 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-15-3 CAPLUS
 CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]methylamino]- (CA INDEX NAME)




RN 151954-16-4 CAPLUS
 CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
 b]pyridin-3-yl)methyl]phenyl]methylamino]- (CA INDEX NAME)


L6 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-17-5 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino]- (CA INDEX NAME)



RN 151954-18-6 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino]- (CA INDEX NAME)




RN 151954-20-0 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-22-2 CAPLUS
CN Benzeneacetic acid, α -[(cyclopropylmethyl)[4-[(2-ethyl-5,7-dimethyl-


L6 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)



IT 137421-60-4P 137421-61-5P 137421-62-6P
137421-63-7P 137421-64-8P 137421-65-9P
137421-66-0P 137421-67-1P 137421-68-2P
137421-69-3P 137421-70-6P 137421-71-7P
137421-72-8P 137421-73-9P 137421-74-0P
137421-75-1P 137421-76-2P 137421-77-3P
137445-56-8P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as intermediate for angiotensin II antagonist)
RN 137421-60-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine,
2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]-
(CA INDEX NAME)




RN 137421-61-5 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 137421-62-6 CAPLUS
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-


L6 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
yl)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137421-63-7 CAPLUS
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 137421-64-8 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-methyl- (CA INDEX NAME)




RN 137421-65-9 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]-, methyl ester (CA INDEX NAME)




RN 137421-66-0 CAPLUS


L6 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)
CN Carbamic acid, ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137421-67-1 CAPLUS
CN Benzenamine, N-ethyl-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 137421-68-2 CAPLUS
CN Benzeneacetic acid, α -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




RN 137421-69-3 CAPLUS
CN Carbamic acid, [4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137421-70-6 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-propyl- (CA INDEX NAME)




RN 137421-71-7 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino]-, methyl ester (CA INDEX NAME)




RN 137421-72-8 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




RN 137421-73-9 CAPLUS



RN 137421-77-3 CAPLUS
CN Benzeneacetonitrile, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino]- (CA INDEX NAME)




RN 137445-56-8 CAPLUS
CN Benzeneacetic acid, α -[2-propen-1-yl[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.
FORMAT


CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl](2-methylpropyl)amino]-, methyl ester (CA INDEX NAME)



RN 137421-74-0 CAPLUS
CN Benzeneacetic acid, α -[(cyclopropylmethyl)[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)



RN 137421-75-1 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl](1-methylpropyl)amino]-, methyl ester (CA INDEX NAME)



RN 137421-76-2 CAPLUS
CN Benzeneacetic acid, α -[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl](1-methylethyl)amino]-, methyl ester (CA INDEX NAME)


ACCESSION NUMBER: 1974:497744 CAPLUS
DOCUMENT NUMBER: 81:97744
ORIGINAL REFERENCE NO.: 81:15441a,15444a
TITLE: Masked antifoggants
INVENTOR(S): Bloom, Stanley M.; Rogers, Howard Gardner
PATENT ASSIGNEE(S): Polaroid Corp.
SOURCE: Brit., 17 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1356142	A	19740612	GB 1971-9593	19710415
PRIORITY APPLN. INFO.:			GB 1971-9593	19710415

AB Benzotriazole antifoggants were masked at the active site by reacting with alkyl- or (alkoxysulfonamido)benzoyl chloride. The masking chain was removed at a temperature dependent rate in aqueous alkaline developing solns. Thus,

6-bromo-3-[4-(hexadecanesulfon-amido)benzoyl]-5-methyl-4-azabenzimidazole, added to a diffusion transfer photog. emulsion, made the antifoggant available in greater quantities at higher processing temps., giving improved color balance in the developed product, and an addnl. degree of stabilization over the unmasked antifoggant. Preparation of 7 other masked


antifoggants was described.
IT 33007-71-5
RL: USES (Uses)
(photog. fog inhibitor precursor, alkaline solution-activatable)
RN 33007-71-5 CAPLUS
CN 1-Hexadecanesulfonamide,
N-[4-[(6-bromo-5-methyl-3H-imidazo[4,5-b]pyridin-3-yl)carbonyl]phenyl]- (CA INDEX NAME)



L6 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1971:428258 CAPLUS
DOCUMENT NUMBER: 75:28258
ORIGINAL REFERENCE NO.: 75:4451a,4454a
TITLE: Photographic products comprising alkali-hydrolyzable
antifoggant precursors
INVENTOR(S): Bloom, Stanley M.; Rogers, Howard Gardner
PATENT ASSIGNEE(S): Polaroid Corp.
SOURCE: U.S., 13 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3575699	A	19710420	US 1968-756838	19680903
PRIORITY APPLN. INFO.:			US 1968-756838	A 19680903

GI For diagram(s), see printed CA Issue.
AB Deactivated antifoggants for incorporation in a photog. system such as a diffusion transfer film have the general formula I, where Y is CH or N, X is N or CR and R is H or alkyl of less than C6, and Z is an alkali-hydrolyzable deactivating group. Z is removed by hydrolysis on contact with the alkaline processing composition at a rate dependent on temperature and independent of exposure and development. Z is comprised of acyl or β -acylalkyl groups.
IT 33007-71-5
RL: USES (Uses)
(photographic emulsions fog inhibitor precursor)
RN 33007-71-5 CAPLUS
CN 1-Hexadecanesulfonamide,
N-[4-[(6-bromo-5-methyl-3H-imidazo[4,5-b]pyridin-3-yl)carbonyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS
RECORD
(3 CITINGS)

=>

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

200.40

424.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-25.23

-25.23

STN INTERNATIONAL LOGOFF AT 10:31:35 ON 11 FEB 2011